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      Since the 1990’s, there has been an exponential rate of growth of publications regarding mass 
spectrometry as a means for bacterial identification.  The use of matrix assisted laser desorption ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) as a high throughput, cost-effective alternative to 
conventional methods in clinical diagnostics has been the basis for a large portion of these.  Current 
techniques for routine bacterial identification involve culture-, biochemical-, and molecular-based 
methods such as, Gram staining, catalase and oxidase activity tests, and PCR assays.  While all of these 
are established methods with proven success of positive identification each has its respective limitation. 
       Antimicrobial susceptibility testing is of particular interest to improve clinical outcomes and limit the 
spread of bloodstream infections therefore requiring a need for a rapid and accurate means for testing.   
In order to address this, our ongoing work with metal oxide laser ionization mass spectrometry (MOLI 
MS) and phage-based mass spectrometry offers an approach to accomplish simultaneous identification 
and antibiotic resistance profiling.  The five main studies in this paper address the primary entities 
required for building a functional bacterial identification platform for MALDI MS.   
      The second chapter focuses on the investigation of six metal oxide catalysts for effective cleavage and 
laser ionization of bacterial cell wall phospholipid extracts. Following evaluation of the six catalysts, 
CeO2 was found to be the most stable over time and reproducibly generated fatty acid profiles. A suite of 
ten bacteria, provided cross validation results of analysis of 100% correct correlation for negative-ion 
data.  Using analysis of variance–principal component analysis (ANOVA–PCA), four sample sets 
collected with stored catalyst at 0, 8, 24, and 504 h showed no effect based on long-term catalyst 
degradation. Supervised learning by a fuzzy rule-building expert system (FuRES) that was validated with 
training and prediction set partitions independent of CeO2 age and unsupervised data analysis using a 
dendrogram of Euclidean distance confirmed that the CeO2 catalyst age had no effect on the fatty acid 




      CeO2-facilitated fatty acid profiling, using MOLI MS, was compared to protein profiling using the 
commercial Bruker Biotyper platform.  Four datasets, Enterobacteriaceae, Acinetobacter, Listeria, fungi 
were processed by principal component analysis (PCA) and validated using leave-one-spectrum-out 
cross-validation (LOSOCV) to test the method’s efficacy.  These tests revealed 100% correct 
classification.  In comparison, protein profile data from the same bacteria yielded 32%, 54%, 67%, and 
33% mean species-level accuracy using two MALDI-TOF MS platforms, respectively. In addition, 
several pathogens were misidentified by protein profiling as non-pathogens and vice versa. These results 
suggest novel CeO2-catalyzed lipid fragmentation readily produced (i) taxonomically tractable fatty acid 
profiles by MOLI MS, (ii) highly accurate bacterial classification and (iii) consistent strain-level ID for 
bacteria that were routinely misidentified by protein-based methods.   
      To evaluate identification and antibiotic resistance determination capabilities of MOLI MS, fifty 
Staphylococcus isolates were evaluated.  This genus was chosen specifically due to the increased 
occurrence of S. aureus infections, specifically the acquired susceptibility to �-lactam antibiotics.  Leave-
one-spectrum-out cross-validation indicated 100% correct assignment at the species and strain level. 
Preliminary analysis differentiating MRSA from MSSA demonstrated the feasibility of simultaneous 
determination of strain identification and antibiotic resistance.   
      As an alternative approach, phage amplification detected by MALDI-TOF MS was investigated for 
rapid and simultaneous Burkholderia pseudomallei identification and ceftazidime resistance 
determination. B. pseudomallei ceftazidime susceptible and resistant ΔpurM mutant strains Bp82 and 
Bp82.3 were infected with broadly targeting B. pseudomallei phage ϕX216 and production of the m/z 
37.6 kDa phage capsid protein observed by MALDI-TOF MS over the course of 3 h infections. This 
allowed for reproducible phage-based bacterial ID within 2 h of the onset of infection. MALDI-TOF MS-
measured time to detection correlated with in silico modeling, which predicted an approximate 2 h 
detection time. Ceftazidime susceptible strain Bp82, while detectable in the absence of the drug, owing to 
the reliance of phage amplification on a viable host, was not detectable when 10 µg/mL ceftazidime was 
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added at the onset of infection. In contrast, resistant strain Bp82.3 was detected in the same 2 h timeframe 
both with and without the addition of ceftazidime. 
      The final chapter offers a modified phage-based approach applied for the detection of pathogenic 
enterococci. An extensive host range study of vancomycin-resistant and -sensitive strains revealed 
promising phage candidates which were probed for unique peptide fragments by MALDI MS.  Antibiotic 
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CHAPTER 1  
AT THE FOREFRONT OF CLINICAL DIAGNOSTICS WITH MALDI-TOF MS 
1.1. Introduction 
Antimicrobial therapy is at the forefront of bacteria-based research due to the growing need to limit 
the spread of infection due to bioterrorism, contamination of food, and clinical infections1-3.  Two main 
paths exist for patients with bacterial infections: the first involves identification of the pathogen of interest 
and secondly, the proper therapeutic treatment course must be chosen4,5.  Current techniques for routine 
bacterial identification involve culture-, biochemical-, and molecular-based methods such as, Gram 
staining, catalase and oxidase activity tests, and PCR assays.  While all of these are established methods 
with proven success of positive identification, each has its respective limitation6,7.  Culture-based methods 
offer high specificity and relatively low costs but the lengthy turnaround time and possible incorrect 
deductions of sample homogeneity lead to delays in the initiation of treatment8,9.  Biochemical assays that 
involve analyzing specific chemical responses of bacteria to a myriad of tests have been developed into 
commercially available systems, such as the bioMerieux API-IDENT and the American Hospital Supply 
Corporation MicroScan System, in an attempt to increase the ease of use10-12.  The lack of species-level 
differentiation due to similar responses among closely-related phylotypes are among the limitations to this 
method.  In addition, both of these methods require secondary susceptibility testing for diagnosis 
increases the turnaround time more than two-fold.  To address some of the above-mentioned 
shortcomings, polymerase chain reaction (PCR)-based methods analyzing specific genetic markers have 
been explored.  The common targets for bacterial identification include those coding for ribosomal RNA, 
elongation factors, or RNA polymerase; by targeting genes specific to mechanisms of acquired resistance, 
antibiotic susceptibility can also be determined using this method13-15.  PCR permits identification but in 
some cases multiple targets must be explored before species level identification can be determined.  The 
high level of expertise and expenses required for analysis are not ideal for clinical settings.  The search 
for a high throughput, cost effective approach that is user friendly but can still accurately identify bacteria 
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has brought MALDI-TOF MS to the forefront.  This review focuses specifically on the frontrunners for 
routine clinical applications of MALDI-TOF MS.   
1.2. MALDI-TOF MS Principles 
MALDI-TOF MS has three major components: an ionization chamber responsible for ablation and 
ion formation of samples, a TOF mass analyzer responsible for achieving mass based separation of ions, 
and a particle detector responsible for collecting the desired ions and outputting the results in terms of the 
relative mass to charge ratio (m/z) of each respective ion.  The soft ionization technique of MALDI, as 
opposed to the harsher conditions present in gas chromatography, yields molecular ions which makes this 
method suitable for biomolecules detection16.  Interaction between matrix and sample is crucial for high 
reproducibility and signal intensity.  Commonly used matrices are weak acids that absorb the inherent 
laser energy which makes evaporation and ionization of biomolecules, which are not volatile in their own 
respect, possible.  DHB (2,5-dihydroxybenzoic acid), α-CHCA (α-cyano-4-hydroxycinnamic acid), and 
ferulic acid are the matrices of choice for low-molecular weight peptides and proteins, with each 
responsible for a slightly different purpose.  For identification techniques to be suitable for profiling and 
clinical applications, three major assumptions must hold true: spectral fingerprints of each microorganism 
are unique, spectra must be reproducible, and differentiation factors must be present.  Due to the temporal 
dependence and variable solubility of bacterial proteins as well as the influence of crystallization on 
spectral quality, exact growth conditions and homogeneity of sample and matrix application are crucial in 
ensuring sufficient reproducibility of the method17.  Also, variation in the ionization efficiency of 
different proteins adds to the inability of quantitative measurements by this method.  Because of this 
methods for analysis are limited merely by the differences in relative peak intensity which requires 
increased reproducibility.  Every method for diagnostics requires slightly different protocols; the three 
techniques described here are outlined in Figure 1.1. 
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Figure 1.1. Schematic representation of a) protein profiling, b) lipid profiling, and c) phage profiling 
indicating time of diagnostics. 
     
1.3. Protein Profiling 
      Since its development in the 1980s, MALDI-TOF MS has primarily evolved into an instrument used 
for microbiology applications due to the soft ionization technique and large mass range16,18.  The initial 
attempts to isolate and analyze water-soluble protein profiles of bacterial membranes involved prior 
separation using HPLC, affinity-based magnetic particles or Nafion membranes19-21.  This led to the 
findings introducing the first profiling technique directly from colonies, without lysis or initial 
extraction22.  As can be seen in Figure 2, similarities appear in spectra A, B, and C but there are also 
minor differences that are unique to each species. These characteristic peaks were investigated to find 
indicative biomarkers to differentiate Bacillus spp23.  Holland et al, later supported this assumption using 
reference spectra as well as co-analysis of well-known bacterial species to show high mass ions that were 
consistently unique to species of E. coli and Shigella24.  To further evaluate the use of protein biomarkers 






using 28 relevant species.  This database was tested against 124 clinical and 16 environmental isolates of 
which it correctly identified 138 out of 140 isolates (98.6% accuracy).   
 
  
Figure 1.2. MALDI-TOF MS protein analysis of Bacillus spp, the table outlines the major peaks found for 
each isolate. (Reproduced with permission reference 23) 
 
This concept led to the development of commercial FDA-approved systems such as the Bruker Biotyper 
and bioMerieux VITEK.  The first intensive clinical study involved a total of 1660 strains analyzed using 
the Bruker Biotyper database.  In this study, 95% of the strains were correctly identified to the genus 
level; valid identification required two or more spots providing the same result25.  Van veen et al. 
followed this approach, and also expanded the study to include yeasts, to obtain 85% correct species-level 
identification.  Similar problems were encountered when identifying Streptococcus spp.  and 
Pneumococcus spp. which emphasizes the need for significant database improvement due to the clinical 
consequences of these pathogens26,27.  By implementing an extraction step in prior to MALDI-TOF 
analysis Bessede et al. achieved 97.3% correct identification at the species-level for 1013 clinical isolates, 
this was superior to the 93.2% identification provided by phenotypic methods28.  Several studies have 
found success in analyzing pathogens isolated from urine and blood cultures, the common testing fluids 
used for administering care in clinical samples29-32, as shown in Table 1.1.   
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Table 1.1. Summary of recent protein profiling studies for bacterial identification by MALDI-TOF MS 
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Due to consistent efforts to facilitate increased identification rates and high-throughput capabilities 
specifically for clinical specimens, pre-cultivation steps were introduced.  Idelevich et al. implemented a 
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brief pre-cultivation step on solid Columbia blood agar medium from positive blood cultures to analyze 
both aerobic and anaerobic species.  In this, 128 cultures in total were studied leading to 97% correct 
identification at the species level after just 8 h of incubation.  Reliable identification was achievable in as 
little as 4 h. for gram-negative rods and addition of an ethanol/formic acid extraction prior to MALDI 
analysis decreased the detection time as well.  Stenotrophomonas rhizophila was not identifiable by the 
Biotyper neither in short culture or control samples despite being present in the database.   This method of 
utilizing the biomass following incubation relieves the need for the additional time and cost expenditures 
of full culture methods33.  Analysis time was further decreased using a two-prong approach consisting of 
lysis-filtration method (LFM) followed by VITEK2 MS for identification and antimicrobial susceptibility 
testing.  Upon positive blood culture determination, the broth was processed using by LFM using a 
sulfonic acid-based lysis buffer followed by microfiltration prior to VITEK MS analysis for bacterial 
identification.  After identification, the filtrate was inoculated by the VITEK2 for full panel antimicrobial 
susceptibility testing and compare to results given by conventional methods.  Out of 100 samples tested, 
the VITEK MS yielded 94% correct identification at the species level and the VITEK2 resulted in 93.5% 
category agreement with 3% major error of antimicrobials tested.  The problematic organisms were 
Proteus mirabilis, Serratia marcescens, Staphylococcus epidermidis, and Pseudomonas aeruginosa34.  
Barnini et al. attempted a ‘direct’ method by removing the pre-cultivation step and harvesting the bacteria 
directly from serum separator tubes of positive blood cultures.  The accuracy of this method was 
measured in concordance with the SepsiTyper method (Bruker ethanol/formic acid extraction) as was 
used in Idelevich’s study.  The ‘direct’ method yielded species-level scores for 95.9% and 32% of Gram-
negative and -positive cocci respectively.  Although the method only takes 30 minutes for identification, 
after a positive blood culture, it had problems identifying Pseudomonas aeruginosa, Micrococcus spp., 
Stenotrophomonas spp., and Acinetobacter baumannii.  This study also pointed out an issue with Gram 
staining in that 19% of the cultures were determined to be polymicrobial by testing and subculture but 
were labeled as monoculture by gram stain35.                   
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1.4. Lipid Profiling 
Due to the numerous combinations of acyl groups and polar head groups, phospholipids have been 
used for chemotaxonomic fingerprinting for over 30 years36-38.  Traditionally lipid analysis has been done 
using chromatographic techniques, but the laborious sample pretreatment has driven the need for a rapid 
technique capable of analyzing these samples.  Ishida et al. initially introduced this concept into the field 
of MALDI-TOF MS analyzing whole cell bacteria of the family Enterobacteriaceae using sodium iodide 
as a pretreatment reagent39.  By pretreating the samples with trifluoroacetic acid, the study was expanded 
to include the thicker peptidoglycan layers of gram-positive bacteria and zooplankter to show successful 
detection of phosphatidylethanolamines (PEs) and phosphatidylglycerols (PGs)40-42.  Implementing 
preparative separation by thin-layer chromatography to investigate the suppression effects of 
phosphatidylcholines on other phospholipids allowed for a broad-scale analysis of lipids43.  Due to the 
limited ionization of traditional matrices, Calvano et al. demonstrated the applicability of using a ‘proton 
sponge’, 1,8-bis(dimethylamino)naphthalene, as an alternative matrix for the ionization of fatty acids and 
lipids in negative-ion reflectron mode.  After accomplishing ionization in the form of deprotonated lipid 
standards, it was shown that minor differences in the amounts of glycolipids, PGs and cardiolipins were 
observable in the spectra of Lactobacillus sanfranciscensis and plantarum44.  A similar study aimed at 
eliminating the background attributed to matrix interference for the analysis of glycerides focused on 
metal oxides, NiO and MgO specifically.  NiO proved useful for studying mono,-, di-, and tri-glycerides, 
phospholipids, and carbohydrates since it produced mostly molecular species45.  Spectra from produced 
sodiated molecular ions as well for both the lipid standards and the more complex mixtures, such as 
vegetable oil and lipid extracts of bacteria, showing the feasibility of the method for ionization of lipids.  
Several studies have shown the implication of saponification-based reactions prior to MALDI analysis to 
analyze fatty acid components of lipid standards and bacterial extracts, in attempts to replicate the results 
from pyrolysis-gas chromatography and the common MIDI technique46-48.  By implementing calcium 
oxide as a catalyst and matrix replacement, referred to as MOLI MS, Voorhees et al. discovered that 
9 
 
transesterification of lipid standards into their fatty acid components could facilitate bacterial 
identification49.  Application of a simple methanol/chloroform extraction, modified from the well-known 
Bligh-Dyer solvent50, prior to MOLI MS resulted in the generation of fatty acid profiles for ten bacterial 
isolates (five gram-positive and five gram-negative) shown in Table 1.2.   
Table 1.2. Bacterial phylotypes used for MOLI MS. 
 
 
Figure 1.3 (a-d) shows representative spectra for four of the ten isolates studied.  As visual examples, all 
isolates possessed similar fatty acids (C16:0, C18:0, C14:0, etc.) but differences in the relative abundance 
of the fatty acids was observed.  Figures 1.3b and 1.3c illustrate differentiation of B. anthracis and E. coli 
by the appearance of C15:0 as the major fatty acid for B. anthracis while C16:0 resides as the major fatty 
acid for the latter.  Visual analysis of the respective ratios of fatty acids provides a qualitative basis for 
bivariate analysis, but multivariate statistics were needed to process more complex data sets, Figure 1.3e.  
Principal components analysis of the ten bacteria showed that replicates of each species plotted together 
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in their own space revealing that the profiles were unique and reproducible.  Classification by leave-one-
spectrum-out cross-validation (LOSOCV) yielded 94% accuracy at the species level51.   
 
Figure 1.3. Representative spectra of ten bacteria by MOLI MS and PCA. a) E. faecalis, b) B. anthracis, 
c) E. coli, d) Y. pestis, and e) 3-dimesional PCA plot.   
 
Although high accuracy was achieved using MOLI MS, tighter clustering between replicates is necessary 
to expand this method for strain-level identification.  This requires in-depth studies of the catalyst and 
extraction methods to improve overall reproducibility. 
1.5. Phage Profiling 
      Phage amplification has several promising characteristics that overcome many of the shortcomings 
associated with protein profiling and even lipid profiling.  The sensitivity, specificity, and time to positive 
identification of phage amplification allow for simultaneous strain-level identification and antibiotic 
resistance determination provided the necessary resources are available.  Since phages have a relatively 
simple and robust protein structure, strict culture conditions are not as crucial.  The ecological diversity of 
phages offers a variety of phages specific to different hosts that allows for controlled adaptation of the 
detection level.  Amplification events of phages from each infection cycle, shown in Figure 1.4, result in 
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the propagation of progeny phage (burst size) which drastically lowers the detection limit of the bacterial 
host through indirect detection of the phage as a secondary biomarker.  The replication cycle and burst 
size is specific to each phage-host combination.  Initial studies incorporating the concept of phage 
amplification with MALDI-TOF MS as the source of detection involved initial affinity capture techniques 




Figure 1.4. Phage amplification diagram showing a burst of progeny phage and positive identification of 
φX216. (Reproduced with permission reference 224)  
 
      The first study utilized magnetic particles bound with host-specific antibodies to isolate the bacteria of 
interest prior to phage addition and subsequent MALDI analysis.  By analyzing for the phage capsid 
protein, as opposed to ribosomal proteins as described above, the spectrum is simplified to one major 
peak that is significantly amplified53.  Rees et al. further advanced the technique so that an isolation step 
was no longer required.  In short, the limit of detection for MS2 and MPSS phages, specific for E. coli 
and Salmonella spp. respectively, was initially determined on the MALDI-TOF MS to establish the phage 
input level.  The MS2 capsid protein appeared at 13.7 kDa and the MPSS-1 capsid protein appeared at 
13.5 kDa giving a positive reference for identification.  Identification of each bacterium was individually 
investigated by inoculating a single bacterium at a time with a solution of mixed phage and incubating the 
culture for 3 h. to allow for phage amplification.  In the instance of E. coli only a single protein peak at 
13.7 kDa was observed; the same was true in the case of Salmonella spp., with the exception of the peak 
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appearing at 13.5 kDa.  To test the limits of the method, a single sample containing a mixed culture of E. 
coli and Salmonella spp. at a concentration of 105cells/mL was inoculated with the mixed phage solution 
which showed characteristic proteins for both MS2 and MPSS-1, Figure 1.554.   
 
Figure 1.5. MALDI spectra of (a) a mixture of E. coli, Salmonella spp., MS2, and MPSS1 immediately 
after the combination of all three constituents and (b) the same mixture after 3 h of incubation. 
(Reproduced with permission reference 54) 
 
This indicates that the presence of multiple bacteria, as is commonly found in clinical blood cultures, or 
bacteriophages does not adversely affect phage amplification.  Broad screening of a phage-host library 
would assist in the widespread implementation in clinical laboratories. 
1.6. Overview of Dissertation 
Mass spectrometry has gained growing emergence in the field of bacterial identification over the last 
two decades.  The use of matrix assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) as a high-throughput, cost-effective alternative to conventional methods in clinical 
diagnostics has been the basis for a large portion of this.  Initial work analyzing spectral patterns from 
whole cell bacterial isolates, originating here at Colorado School of Mines, has led to the development of 
several commercialized MALDI-TOF MS systems, two examples are the Bruker Biotyper and Shimadzu 
Axima.  These platforms utilize protein profiling as the basis for identification, leading to an exponential 
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rate of growth in publications in the field.  Among pressing concerns, due to the spread of hospital-
acquired bloodstream infections, is a rapid and accurate means for antimicrobial susceptibility testing.  In 
2016 congress implemented an initiative appropriating $160 million towards the improvement, detection, 
response, and containment of antibiotic resistant bacterial infections.  This push for rapid detection to aid 
in the improved treatment of bacterial infections is the guiding motivation for this work.  This dissertation 
specifically aims to develop a rapid, high-confidence method capable of screening pathogens for 
identification and antibiotic susceptibility.  Due to initial culturing requirements, identification in less 
than 24 h. serves as the benchmark.  
      The first step in developing a functioning method for fatty acid profiling is the discovery of a suitable 
catalyst and matrix replacement for MALDI-TOF MS.  Chapter 2 investigates six metal oxide catalysts 
for effective cleavage and laser ionization of bacterial cell wall phospholipid extracts. Calcium oxide has 
been utilized in the past for this application, but suffered from degradation of catalytic activity. Following 
evaluation of the six catalysts, CeO2 was found to be the most stable over time and produced fatty acid 
profiles of bacterial pathogens similar to freshly activated CaO. A suite of ten bacteria, previously studied 
using CaO catalysis, provided cross validation results of analysis of 97% correct correlation for negative-
ion data. Cerium oxide catalysis studies yielded cross validation results of 100%. Using analysis of 
variance–principal component analysis (ANOVA–PCA), four sample sets collected with stored catalyst at 
0, 8, 24, and 504 h showed no effect based on long-term catalyst degradation. Supervised learning by a 
fuzzy rule-building expert system (FuRES) that was validated with training and prediction set partitions 
independent of CeO2 age and unsupervised data analysis using a dendrogram of Euclidean distance 
confirmed that the CeO2 catalyst age had no effect on the fatty acid mass spectral profiles.  
      To test the efficacy of the newly-developed CeO2-facilitated fatty acid profiling, using MOLI MS, it 
was compared to protein profiling using the commercial Bruker Biotyper platform.  Three datasets, 
Enterobacteriaceae, Acinetobacter, and Listeria were processed by principal component analysis (PCA) 
and validated using leave-one-spectrum-out cross-validation (LOSOCV) to test the method’s 
efficacy.  These tests revealed 100% correct classification.  In comparison, protein profile data from the 
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same bacteria yielded 32%, 54% and 67% mean species-level accuracy using two MALDI-TOF MS 
platforms, respectively. In addition, several pathogens were misidentified by protein profiling as non-
pathogens and vice versa. These results suggest novel CeO2-catalyzed lipid fragmentation readily 
produced (i) taxonomically tractable fatty acid profiles by MOLI MS, (ii) highly accurate bacterial 
classification and (iii) consistent strain-level ID for bacteria that were routinely misidentified by protein-
based methods.   
      Chapter 4 describes the use of metal oxide laser ionization mass spectrometry (MOLI MS) fatty acid 
profiling as a rapid, simultaneous identification and antibiotic resistance determination method.  Fifty 
Staphylococcus isolates were evaluated by MOLI MS.  This genus was chosen specifically due to the 
increased occurrence of S. aureus infections, specifically the acquired susceptibility to �-lactam 
antibiotics.  Leave-one-spectrum-out cross-validation indicated 100% correct assignment at the species 
and strain level. Fuzzy rule building expert system classification and self-optimizing partial least squares 
discriminant analysis, with more rigorous evaluations, also consistently achieved greater than 94 and 84% 
accuracy, respectively. Preliminary analysis differentiating MRSA from MSSA demonstrated the 
feasibility of simultaneous determination of strain identification and antibiotic resistance.  
      In chapter 5, phage amplification detected by MALDI-TOF MS was investigated for rapid and 
simultaneous Burkholderia pseudomallei identification and ceftazidime resistance determination. B. 
pseudomallei ceftazidime susceptible and resistant ΔpurM mutant strains Bp82 and Bp82.3 were infected 
with broadly targeting B. pseudomallei phage ϕX216 and production of the m/z 37.6 kDa phage capsid 
protein observed by MALDI-TOF MS over the course of 3 h infections. This allowed for reproducible 
phage-based bacterial ID within 2 h of the onset of infection. MALDI-TOF MS-measured time to 
detection correlated with in silico modeling, which predicted an approximate 2 h detection time. 
Ceftazidime susceptible strain Bp82, while detectable in the absence of the drug, owing to the reliance of 
phage amplification on a viable host, was not detectable when 10 μg/mL ceftazidime was added at the 
onset of infection. In contrast, resistant strain Bp82.3 was detected in the same 2 h timeframe both with 
and without the addition of ceftazidime. 
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      In chapter 6, a modified phage-based approach is applied for the detection of pathogenic enterococci. 
An extensive host range study of vancomycin-resistant and -sensitive strains revealed promising phage 
candidates which were probed for unique peptide fragments by MALDI MS.  Antibiotic resistance 
determination was determined by successful phage amplification. 
1.7. Chapter Contributions 
      Chapter 1 and 7 were the only chapters solely authored by Nicholas R. Saichek. The rest of the 
chapters required essential input from colleagues and collaborators.  In chapter 2, Nicholas R. Saichek 
conducted all MOLI MS, catalyst studies, helped with the writing of the manuscript and responses to the 
reviewers, and figure preparation. For chapter 3, Nicholas R. Saichek conducted all MOLI MS 
experiments, assisted with PCA and cross validation results, and helped with review of the manuscript as 
well as responses to the reviewers’ comments.  In chapter 4, Nicholas R. Saichek conducted all 
experiments, helped with data analysis, prepared all figures, wrote the manuscript and responded to 
reviewers comments. In chapter 5, Nicholas R. Saichek helped with some writing of the manuscript, 
performed growth, amplification and modeling experiments, as well as conducted MALDI-TOF MS 
analysis. Nicholas R. Saichek wrote and submitted chapter 6, conducted growth and amplification 












CHAPTER 2  
COMPARISON OF METAL OXIDE CATALYSTS FOR PYROLYTIC MOLI-MS BACTERIAL 
IDENTIFICATION 
Published manuscript from Journal of Analytical and Applied Pyrolysis (Accepted Oct. 2014)1 
Kent Voorhees2, Nicholas Saichek2,3, Kirk Jensen2, Peter Harrington4, and Christopher Cox2,5 
2.1. Introduction 
      Fatty acid profiling has been used for bacterial identification since the 1960s55.  The original work 
utilized an ex situ method involving saponification followed by derivatization of cell wall fatty acids to 
form fatty acid methyl esters (FAMEs) followed by gas chromatography analysis 56.  Later, an in situ 
thermochemical process using tetramethyl ammonium hydroxide (TMAH) was developed, which 
significantly reduced sample analysis time to less than three min for Curie-point pyrolysis-mass 
spectrometry (PyMS) 57,58.   
      It has been observed during lipid analysis by matrix-assisted laser desorption ionization time-of-flight 
mass spectrometry (MALDI-TOF MS), that sufficient heat was generated to pyrolyze the sample59.  
During an investigation of TMAH as a methylating agent for MALDI-TOF MS with CaO as a matrix, 
lipid cleavage was observed.  Tandem MALDI analysis identified the resulting cleavage products as 
calcium fatty acid adducts59.  It was later determined that a strong base, acid, or heat was necessary to 
activate CaO59,60.  Using activated CaO, monoacylglycerides, diacylglycerides, triacylglycerides, 
phospholipids, as well as bacterial and algal extracts, produced peaks for their constituent fatty acids61.  In 
addition, spectra from bacterial and algal extracts were found to be reproducible, which suggested that 
this technique could be used for microbial fatty acid profiling.     
                                                          
1 Reproduced with permission from: J. Anal. Appl. Pyrolysis. 2015, 113, 78-83. 
2 Department of Chemistry, Colorado School of Mines, Golden, Colorado 80401, United States 
3 Graduate student and primary researcher 
4 Center for Intelligent Chemical Instrumentation, Ohio University, Athens, Ohio 45701, United States 
5 Corresponding author 
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In a follow up publication, five Gram-positive and five Gram-negative bacteria were analyzed using CaO 
in positive- and negative-ion MALDI-TOF MS modes followed by principal component analysis 
(PCA)62.  PCA showed distinct clusters for five replicates of each bacterial species with 94% cross 
validation correlation of positive-ion data.   Negative-ion data yielded a higher classification rate of 97% 
and exhibited less within group variation than the positive-ion data. 
     The current state-of-the-art for MALDI MS-based clinical microbial identification centers on protein 
profiling.  Three commercial protein databases63 have been developed for this application64.  Two 
companies, Bruker and BioMérieux, have received European ‘CE’ mark and US Food and Drug 
Administration approval for use in clinical laboratories.  These databases contain multiple profiles of over 
3000 bacteria and claim over 98% correct identification according to company literature.  In an analysis 
of 1,371 clinical isolates, a peer-reviewed comparison of the Bruker Biotyper to conventional typing 
methods found 93.2 % were putatively identified to the species level65.  A second study focused 
specifically on Gram positive rods, which typically have lower Biotyper identification rates compared to 
Gram negatives or Gram positive cocci66, reported 79.1% of 215 isolates were correctly identified at the 
species level67.   
       The most important criterion for a diagnostic technique centers on the fact that each bacterial protein 
profile is unique and reproducible, which depends on bacterial growth conditions and instrument stability68.  
In the case of a catalytic process such as metal oxide lipid cleavage, catalyst stability must also be 
considered.  The following paper describes the degradation associated with CaO stability and the screening 
of five additional metal oxide catalysts. 
2.2. Experimental Section  
 Bacterial Strains and Culture Conditions 
       Table 2.1 summarizes the bacteria used in this study62.  All bacterial strains were cultured overnight 
in brain heart infusion (BHI) medium (BD-Difco, Franklin Lakes, NJ) at 37°C.  Following incubation of 
broth cultures, bacteria were streaked onto agar plates and incubated for 22 h.  Extracts of single colonies 
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were immediately prepared upon removal from the incubator. To minimize culture conditions as a 
variable in fatty acid analysis, these parameters were used as a carefully controlled, standardized method 
for all experiments.  
Table 2.1. Bacterial phylotypes used 
 
 Lipid Extraction 
       Individual colonies were suspended in 100 μL of a 33/66 v/v% methanol/chloroform mixture 
(Pharmco-AAPER, Shelbyville, KY and Fisher, Pittsburgh PA, respectively) and vortexed for 2 min at 
3200 rpm.  Phase separation was achieved by addition of 100 L of phosphate buffer saline (PBS, pH 7.4) 
followed by an additional 60 s of vortexing and cell debris removal by centrifugation for 30 s at 1400 x g.  
The resulting organic fraction was then removed for MALDI-TOF MS analysis. 
 Catalysts 
      The following metal oxides were investigated for their combined catalytic properties and temporal 
stability during bacterial phospholipid cleavage:  calcium oxide. purity 99.4% (Nano-Active Inc. 
Manhattan KS), magnesium oxide, purity 99.6% (Nano-Active Inc,), nickel oxide, purity 99.8% (Sigma 
Aldrich, St. Louis, MO), cerium (IV) oxide, purity 99.9% (Cerac, Milwaukee,WI), barium oxide, purity 
99.5% (Cerac), and strontium oxide, purity 99.5% (Alfa Aesar, Ward Hill, MA).  Thermal activation was 
performed on CaO, BaO, and SrO in an open-air tube furnace at 800 °C for 3 h while NiO and MgO were 
 
Gram positive Strain Source 
Bacillus anthracis Sterne Armed Forces Institute of Pathology 
Clostridium putrefaciens ATCC 25786 ATCC 
Enterococcus faecalis V583 University of Oklahoma Health Sciences Center 
Listeria monocytogenes ATCC 19112 ATCC 
Staphylococcus aureus ATCC 27660 ATCC 
Gram negative 
Acinetobacter baumannii AC54 Felix d’herelle Reference Center Viruses 
Escherichia coli ATCC 15597 ATCC 
Francisella tularensis LVS Colorado State University 
Salmonella typhimurium ATCC 13311 ATCC 
Yersinia pestis A1122 CDC Division of Vector-borne Diseases 
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heated to 350 °C to remove surface water.  Activation of CeO2 was not required.  All catalysts were 
stored in a desiccator under vacuum.    
     An investigation of the stability of the CaO, BaO, and SrO was conducted by taking MALDI-TOF MS 
measurements (called metal oxide laser ionization-MS (MOLI-MS)) of the same bacterial phospholipid 
extracts at 0, 8, and 24 h post activation.  Cerium oxide spectra were generated at 0, 8, 24, and 504 h, 
where the catalyst for t=0 was obtained directly from the manufacturer’s bottle.  This same catalyst was 
stored in a vacuum dessicator and removed for the 8, 24, and 504 h time points. 
 Mass Spectrometry 
      Samples were prepared for MOLI-MS as previously described61.  Briefly, 100 mg catalyst was added 
to one mL of n-hexane (Sigma-Aldrich).  One µL was then removed from the bottom of the resulting 
slurry and spotted on a stainless steel MALDI sample plate followed by 2 µL of lipid extract.  Other 
sample preparations such as overlay and sandwich methods, did not improve the data quality. 
     Mass spectrometric measurements were acquired in positive- and negative-ion modes with a Bruker 
Ultraflextreme MALDI-TOF mass spectrometer (Bruker Daltonics, Billerica, MA) equipped with a 355 
nm Nd:YAG laser.  Spectra were collected in reflector mode at 4000 resolution with a grid voltage of 
50.3%, a delayed extraction time of 120 ns, and a low-mass cutoff of 150 Da.  Five replicate spectra were 
collected for each bacterium as 500 shot composites at a sampling frequency of 1 kHz using automated 
laser rastering.   
 Data Analysis 
      Selected fatty peaks (Table 2.2) from each spectrum were exported from the instrument in ASCII 
format and processed by two procedures.  In the first, an in-house program centroided and normalized the 
spectra to total intensity, and selected fatty acid peaks prior to PCA.  Processed data were recorded in a 
tab-delimited format and imported directly into R Version 3.0.2 (The R Foundation for Statistical 
Computing, Vienna, Austria) as a data frame.  PCA was performed using the prcomp() function with an 
argument passed to return rotated variables; data were automatically mean-centered by prcomp().  Data 
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were plotted using the built-in plot() function in R.  Leave-one-out cross validation was performed on the 
input data by passing the appropriate argument to the linear discriminate analysis function lda(), which is 
part of the Modern Applied Statistics with S package69.  Results from lda() returned class assignment 
based on supervised learning. 
Table 2.2. Fatty Acids used in Principal Component Analysis 































       In supervised analysis, the data were imported into MATLAB R14a using the 150 unprocessed 
spectra as text files.  The spectra were normalized to unit vector length and analyzed using a fuzzy rule-
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building expert system (FuRES) 70 with customized MATLAB scripts and functions.   The FuRES was 
validated with 100 bootstraps with 3 Latin partitions71,72.  The data were bootstrapped individually and 
also by removing all the replicates that corresponded to the same catalyst age.  The normalized data were 
also used to construct an unsupervised dendrogram using average centroid linkages and minimum 
Euclidean distances.  The normalized mass spectra also were subjected to ANOVA-PCA with bacterial 
species, catalyst age, and interaction as factors.  The statistical significance was measured by using the 
pooled sums of squares method that provides a conservative estimate of significance.  
2.3. Results and Discussion 
MOLI-MS using CaO as a catalyst is known to cleave phospholipids into their fatty acids 59,61.  
Although cross-validation results were above 97% correct classification for the previously referenced 10 
bacteria, for the technique to be useful in the clinical laboratory, the catalyst must be stable over time and 
capable of generating highly reproducible fatty acid profiles.  CaO is known to be susceptible to moisture 
and carbon dioxide poisoning and must be activated prior to use for catalytic pyrolysis of lipids.  It was 
unclear if the catalyst could be stored under vacuum and maintain its original activity.  Figure 2.1 is a 
PCA score plot of the first 2 principal components (PCs) for negative-ion CaO-catalyzed MOLI mass 
spectra of Escherichia coli, Salmonella typhimurium, and Shigella boydii extracts.  Measurements of a 
single extract from each bacterial type were taken over three time points from 0, 8, and 24 h post-thermal 
catalytic activation.   
Although unique spatial groupings corresponding to each time point were observed, the relative 
position of distinct groupings for each bacterial species changed with time, and clearly showed a temporal 
effect on catalyst deactivation.  The overlapping alignment observed for the S. boydii and S. typhimurium 
groupings suggests that these genera may be difficult to differentiate using supervised learning 
techniques.  Table 2.3 summarizes the variance associated with the first six PCs.  Group separation was 





Figure 2.1. CaO reproducibility as a function of time.  Square=E. coli, circle=S. typhimurium, triangle=S. 
boydii.  Red, 0 h; green, 8 h; blue, 24 h. 
 
Because CaO appears to be deactivated even in short time periods, five additional prospective catalysts 
were evaluated for generation of fatty acids from glyceride standards and their overall stability 
investigated over a 24-504 h timeframe.  Nickel oxide and MgO failed to cleave glyceride standards to 
any degree regardless of instrument parameters, rather, molecular species of intact glycerides in both 
positive- and negative-ion modes were observed.  Cerium oxide, BaO, and SrO cleaved the standards 
(data not shown) and BaO and SrO produced both positive- and negative–ion peaks in the same manner 
as previously reported for CaO. However, only negative-ions were observed for CeO2.  This result was 
not surprising because the +4 oxidation state of cerium produces a +3 charge on resulting single fatty acid 
complexes.  The low-mass, non-integer peaks of these complexes places them in a spectral region that 
complicates data analysis.  Based on reactivity and adverse health effects, BaO and SrO were not 
23 
 
investigated beyond our initial screening.  Because it is non-reactive, CeO2 was subjected to further in-
depth studies.   
Table 2.3. Percentage of total variance for CaO reproducibility
 
 
      To determine whether CeO2 demonstrated improved stability over CaO, a time study was conducted 
with the same 10 bacteria listed in Table 2.1.  
 
Figure 2.2. Comparison of catalyst stability as a function of time.  S. typhimurium spectra obtained over 
24 h. using A) CaO and B) CeO2. 
 
      Figure 2.2 contains selected negative ion spectra of Salmonella from 0, 8, and 24 h for the two 
catalysts.  The intensities of the three spectra in Figure 2.2B obtained using CeO2 were consistent with 
each other as a function of time and comparable to the CaO-derived spectrum at time zero in Figure 2.2A.  
Calcium oxide spectra (Figure 2.2B) obtained at 8 and 24 h showed changes in intensity of the individual 
fatty acids and a prominent, unidentified peak at m/z 473, indicating degradation of the catalyst.  Figure 
 





















2.3 shows PCA score plots of CeO2 derived bacterial data and previously published CaO data for the same 
bacteria62. Table 2.4 summarizes the variance associated with the first six PCs for each catalyst.  The 
cumulative variance for the CeO2 data was 92.1% for the first 2 PCs.  
Table 2.4. Comparison of percentage of total variance
 
 
       In contrast, the cumulative variance for CaO was only 73% encompassing 6 PCs.  In the case of the 
CaO data, all combinations (PCs 1 and 2, PCs 1 and 3, etc.) were plotted, however, PCs 1 and 2 gave the 
best separation.   
 
 
Figure 2.3. PCA score plots of 10 bacteria from A) freshly activated CaO and B) Three CeO2 time points, 
0 h, 24 h, 504 h. ( ) A. baumannii, ( ) B. anthracis, ( ) C. putrefaciens, ( ) E. coli, ( ) E. faecalis, ( ) 





















































Comparison of 3D plots of the first 3 PCs for CaO (Fig. 3A) and CeO2 (Figure 2.3B) had similar 
separations (between group variation), however the precision (within group variation) was better using 
CeO2.  Cross-validation using LDA of CeO2-derived fatty acid profiles gave 100% correct classification. 
        
 




       Analysis of variance-principal components analysis (ANOVA-PCA) 73 was used to determine the 
significant factors responsible for differentiation.  The p-value for the mathematical means between 
species was below 10-4.  The storage time of CeO2 and interaction among species factors were highly 
insignificant with p-values close to 1.073. 
      Cluster analysis of the data produced the dendrogram of the Euclidean distances between pairs of 
objects and the cluster averages represented in Figure 2.4.  It is interesting that two distinct clusters were 
observed that almost corresponds to Gram type, which was previously observed by FAME analysis using 
PyMS74.  If E. faecalis and F. tularensis were interchanged, separation of Gram type would be complete.  
Note that the separation that occurs among the species in the dendrogram is natural, and not because of 
unsupervised clustering of the data. 
      A principal component transform (PCT) was used to compress the spectra before FuRES analysis.  
The classification tree in Figure 2.5 is similar in structure to the dendrogram, although the FuRES73 is 
supervised and the cluster analysis was unsupervised.  For the PCT during the bootstrap procedures, 
principal components were calculated from the training data set and prediction data were projected onto 
these components for each bootstrap-partition.   
 
Figure 2.5. FuRES classification tree built from the entire set of normalized spectra. 
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      The results were 100% accurate for classification at the species level.  Further analysis used a 
partition procedure so that each group of spectra collected for a specific catalyst age was removed from 
the model-building step using the same procedure as before of 100 bootstraps and 3 partitions.  Replicate 
spectra from the same catalyst age and species were either in the prediction set or training set, but never 
both at the same time.  Classification accuracy was not affected by CeO2 post-activation time and 
remained at 100%. 
2.4. Conclusion 
In total, six metal oxide catalysts were evaluated for their capacity to reproducibly cleave bacterial cell 
wall phospholipid extracts to their constituent fatty acids followed by negative-ion MOLI-MS.  CaO was 
found to partially degrade in less than one-hour post-activation.  Of the six catalysts evaluated, CeO2 
provided superior stability and reproducibility and required no activation.  An extended time study up to 
504 h using the same fatty acid extract and stored catalyst showed that no difference in fatty acid distribution 
occurred.  A comparison of CaO data collected immediately after activation to CeO2-derived data collected 
over a one-week period showed that similar fatty acid profiles were observed and clearly established the 
stability of the CeO2.  Both supervised and unsupervised classifiers gave 100% accurate species assignment, 











CHAPTER 3  
STRAIN-LEVEL BACTERIAL IDENTIFICATION BY CEO2-CATALYZED MALDI-TOF MS 
FATTY ACID ANALYSIS ANDCOMPARISON TO COMMERCIAL  
PROTEIN-BASED METHODS 
Published manuscript from Nature Scientific Reports (Accepted July 2015)1 
Christopher Cox2, Kirk Jensen2,3, Nicholas Saichek2,4, and Kent Voorhees2,5 
3.1. Introduction 
Protein-based diagnostic bacterial identification by matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) has gained acceptance by the clinical and research 
communities following United States FDA and European Commission CE Mark approval of two 
commercial systems: the Bruker Microflex Biotyper and the bioMérieux VITEK MS.  However, an 
underappreciated drawback exists when using protein profiling to differentiate between closely related 
bacterial species or strains, and, as we show in this report, this method often failed to properly 
differentiate several clinically important species.  These ambiguities are thought to arise primarily 
because closely related species and/or strains express many similar if not identical proteins, but can also 
occur because of a lack of representative spectra in the manufacturer’s database.  To address the 
commonly held assumption that bacterial diagnostics must target proteins, we investigated fatty acid (FA) 
profiling by CeO2-catalyzed metal oxide laser ionization (MOLI) MS as an alternative means of bacterial 
ID.  By focusing on bacterial lipids as diagnostic biomarkers rather than proteins, and by exploiting the 
unusual catalytic propensity of the rare-earth lanthanide CeO2 to cleave lipids to FAs as a novel MALDI 
matrix, we obtained highly accurate and reproducible species- and strain-specific bacterial FA profiles.  
We hypothesize that this was achieved through rapid, in situ conversion of bacterial lipids into FA anions 
                                                          
1 Reproduced with permission from: Sci. Rep. 2015, 5, 10470. DOI: 10.1038/srep10470. 
2 Department of Chemistry, Colorado School of Mines, Golden, Colorado 80401, United States 
3 Graduate student and contributing data analyst 
4 Graduate student and primary researcher 
5 Corresponding author 
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by the 4+ reactive state of cerium using the laser energy inherent to MALDI-TOF MS. Rare earth 
elements have played an increasingly important role in numerous industries because of their unusual 
catalytic, electronic, and magnetic properties75.  Of specific interest, cerium has been increasingly utilized 
in a wide range of applications including fuel and solar cell construction,76,77 automobile catalytic 
converters,78 and as a large-scale catalyst in the hydrogen production and biofuel refining industries79.  
The majority of lanthanides usually exist in a trivalent state.  Cerium can exist in either the +3 or +4 
valence state, making it an exceptional catalyst with myriad enzymatic mimetic properties80,81.  This 
dynamic reactivity is thought to occur because cerium has two partially filled electron subshells, 4f and 
5d, which allows it to shift between valence states82.  While cerium has been used in a range of 
biomedical applications81, to our knowledge, its capacity as a biocatalyst for in situ conversion of 
bacterial lipids into taxonomically viable FAs using MALDI-TOF is novel.  In previous work, we 
investigated catalyst stability and reproducibility of CeO2- catalyzed MOLI MS analysis with biological 
replicates of 10 representative bacteria over a 3-week period83.  ANOVA data clearly demonstrated 
catalyst stability and showed that a combination of biological and technical sample preparation had no 
effect on reproducibility.  MOLI MS allowed high throughput strain-level ID of bacterial samples using 
MALDI instruments already in use in clinical laboratories for protein-based ID.  Here we demonstrate the 
catalytic capability of CeO2 applied to rapid ID compared to the Bruker Biotyper, and provide compelling 
evidence for its use in accurate bacterial ID.  Our protein profiling results, obtained on two independent, 
similarly tuned instruments suggests that in situ MOLI MS analysis of FAs can be used alone or as a 
complimentary technique with existing Biotyper instruments with negative-ion capabilities. 
3.2. Experimental Section 
 Bacterial Strains and Growth Conditions  
      E. coli, Salmonella, and Shigella strains were purchased from the American Type Culture 
Collection (ATCC-Manassas, VA).  Acinetobacter strains were obtained from the ATCC and the Felix 
d’Herelle Reference Center for Bacterial Viruses (University of Laval, Québec, Canada).   
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Listeria strains were purchased from the ATCC or were contributed by Dr. Martin Loessner (Institute of 
Food, Nutrition and Health, Zurich, Switzerland).  Enterobacteriaceae were cultured for 18 hours in Luria 
Bertani (LB) broth (Becton Dickinson Difco, Franklin Lakes, NJ) and streaked to isolation on LB agar.  
Acinetobacter and Listeria were cultured for 18 hours in brain heart infusion broth (BHI, BD-Difco) and 
streaked to isolation on BHI agar.  All incubation was performed at a constant 37oC +/-0.2o in strict 
accordance with Bruker Biotyper SOPs for bacterial cultivation in order to minimize temperature 
fluctuation-induced changes in FA or protein expression.  
 16S rRNA Sequencing and Analysis 
      16S rRNA gene sequencing was used as a simple means to verify the ID of strains in our collection 
prior to FA and protein analysis.  Colonies representing each morphological type were streaked to 
isolation on BHI or LB agar and incubated for 18 hours at 37°C under aerobic conditions.  Following 
incubation, single colonies were suspended in 50 l sterile water, and colony PCR performed using 16S 
rRNA gene eubacterial oligonucleotide primers 27F and 1492R (Integrated DNA Technologies, 
Coralville, IA) to amplify all nine variable regions of the 16s rRNA gene as previously described95.  Each 
50 l PCR mixture was composed of 1 l of colony suspension, 1 l each of 10 M forward primer 27F 
and reverse primer 1492R, 25 l DreamTaq 2X master mix (Thermo Scientific), and 22 l sterile water.  
Thermal cycling conditions consisted of an initial 3-min denaturation step at 94°C, 30 cycles of 94°C for 
30 s, 55°C for 90 s, and 72°C for 2.5 min, and a final 10-min extension at 72°C.  All reactions were 
carried out in 0.2 ml reaction tubes using a Techne TC-412 thermocycler (Techne, Burlington, NJ) and 
PCR products were confirmed by electrophoresis through a 1% agarose gel visualized by ethidium 
bromide staining.  Sequencing reactions were performed by Davis Sequencing (Davis, CA), using an 
Applied Biosystems 3730 DNA Analyzer (Applied Biosystems, Foster City, CA).  Prior to sequencing, 
all PCR products were treated with ExoSAP-It (Affymetrix, Santa Clara, CA).  PCR products were 
sequenced using the same universal eubacterial 16S rRNA primers 27F and 1492R95.  All 16S rRNA 
sequences were compiled and aligned using Geneious 5.5.7 bioinformatics software (Biomatters Ltd, 
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Auckland, New Zealand).  All sequences were compared to the sequences in Ribosomal Database Project 
II (RDP-II)112, using the Sequence Match function and by nucleotide BLAST comparison to the NCBI 
sequence database.  Prior to phylogenetic analysis, each sequence was manually edited by examination of 
its sequencing chromatogram and tested as a possible chimera using Bellerophon113.  Chimeric sequences 
and poor-quality sequences were excluded from further analysis.  Probable isolate ID was determined as 
previously described94-96.  
 Lipid Extraction 
      For CeO2-catalyzed FA analysis, individual colonies (or a few morphologically identical colonies if 
small colony size prevented adequate sample preparation from a single colony) of each species were 
extracted in accordance with Bruker’s SOP for alternative Biotyper whole-cell suspension93 with the 
following modifications: colonies were suspended in 100 L of a 33/66 v/v% methanol/chloroform 
(Pharmco-AAPER, Shelbyville KY and Fischer, Pittsburgh PA, respectively) mixture and vortexed for 2 
minutes to allow for disruption of the cells as previously described114,115.  Phase separation was achieved 
by the addition of 100 L of phosphate buffer saline (PBS) pH 7.4 to facilitate lipid extraction.  Mixtures 
were then vortexed for another 60 seconds and centrifuged briefly prior to MALDI sample plate spotting.   
 Mass Spectrometry 
      Samples were prepared for mass spectrometry as previously described84,85.  Briefly, 100 mg of CeO2 
(Nano-Active Inc. Manhattan KS) was added to one mL of n-hexane.  One µL was then removed from the 
resulting slurry and spotted on a stainless steel MALDI sample plate.  Two µL lipid extract aliquots were 
spotted directly onto activated CeO2 spots.  Negative controls were run on SBA-15 (Sigma-Aldrich, St. 
Louis, MO) to ensure FA spectra were the result of CeO2 catalysis and not from thermal desorption of 
lipids.  All data was obtained in negative-ion mode as previously described85.  
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 FA Data Analysis 
      Twenty-three FA peaks from the mass spectra data were selected, centroided, assigned nominal 
masses, and compiled into a spreadsheet using software written in-house.  The spreadsheet was imported 
into the R Statistics Software program (Ver. 3.0.2, R Foundation, Vienna, Austria) for PCA and leave-
one-out CV.  The prcomp function was used to calculate PCA scores; prcomp mean-centers the data, but 
no auto-scaling was used.  Scores from PCA analysis were plotted using the plot function.  CV was done 
using the lda function from the Modern Applied Statistics with S (MASS) package116 and setting the 
“CV” flag as “True.”  Results from CV are reported as percentages of correct assignments divided by 
total measurements. 
 MALDI Biotyper Sample Preparation 
Five replicates of single morphologically distinct colonies of each strain were collected from agar 
plates and each applied to separate wells on polished stainless steel MALDI target plates (Bruker 
Daltonic, Billerica, MA).  Samples were then overlaid with 1 L of α-cyano-4-hydroxycinnamic acid 
matrix (HCCA) (Bruker) according to the manufacturer’s instructions. MALDI plates were then placed in 
sterile, covered petri dishes and allowed to air dry at room temperature.  
 MALDI Protein Analysis 
       Protein analysis was conducted using Bruker Ultraflextreme and Microflex MALDI-TOF mass 
spectrometers configured to run Bruker Biotyper Real Time Classification (RTC) (v3.0) software 
according to the manufacturer’s instructions.  The Ultraflextreme was detuned to match Microflex 
settings.  Specifically, the ion source was fixed in positive ion mode, sensitivity decreased from 150:1 to 
50:1, and resolution decreased from 25,000 to 1000.  Detector voltage was variably reduced to lower 
signal response and the digitizer sampling rate was lowered from 2 GS/s to 0.5 GS/s in order to match 
Microflex specifications.  Five individual replicates of each strain were independently analyzed by 
automated laser rastering.  The instrument was calibrated using the Bruker Biotyper Bacterial Test 
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Standard (BTS) according to the manufacturer’s instructions.  Bacterial ID results were automatically 
generated as a pdf report for each of three groups of bacterial strains (Enterobacteriaceae, Acinetobacter, 
and Listeria).  Enterobacteriaceae and Acinetobacter were identified using the built-in Bruker Biotyper 
IVD database, while Listeria were analyzed using the Bruker Listeria-specific Biotyper database.  PCA 
was conducted using Biotyper 3.0 analysis tools.  All samples were subjected to a second round of 
Biotyper analysis using a pre-analysis sample extraction as recommended by Bruker and as previously 
described.20  Briefly, single colonies (or a few morphologically identical colonies if small colony size 
prevented adequate MALDI-TOF MS sample preparation from a single colony) were suspended in 30 L 
of 70% ethanol and centrifuged.  Pellets were then resuspended in an equal volume of 70% formic acid 
and vortexed followed by addition of 30 L of 100% acetonitrile.  Resulting suspensions were 
centrifuged and supernatants collected for analysis. 
3.3. Results  
 CeO2-catalyzed MOLI MS Fatty Acid Profiling 
      Because of our early successes using metal oxides for lipid analysis83-85 bacterial genera that were 
known to be problematic for protein profling86-88 were investigated using MOLI MS with CeO2 as an 
alternative means of analysis.  Specifically, isolates of three representative sets of clinically-relevant 
genera belonging to Enterobacteriaceae, Acinetobacter, and Listeria comprised of five replicates each of 
26 strains were analyzed and compared with protein-based IDs obtained on two separate Bruker MALDI-
TOF instruments (Ultraflextreme and Microflex, both running Biotyper 3.0).  In this and previous 
studies,89,90 multivariate statistical methods were used to validate patterns in complex mass spectral data, 
including bacterial FAs.  Score plots from principal component analysis (PCA) of CeO2-catalyzed MOLI 
FA spectra (Fig 3.1 top row) and Biotyper protein spectra (Fig 3.1 bottom row) for Enterobacteriaceae, 





Figure 3.1. Comparison of protein and CeO2-catalyzed fatty acid bacterial identification. 
 
The quality of the data was indicated by the spatial proximity of individual replicates (inner variance) of 
one bacterial type compared to the distances between clusters of the other types (outer variance).  CeO2-
catalyzed MOLI MS data showed distinct clustering of replicates and observable separation between 
categories, which indicated that FA profiles for each strain were unique and distinguishable within the 
species examined in this study.  In contrast, and in agreement with Biotyper ID reports (Tables 3.1-3.3), 
PCA plots of corresponding protein spectral data showed limited separation and poor clustering even at 
the genus level.  In some cases poor precision of replicate protein spectral data was also apparent. 
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       Leave-one-out cross validation (CV) by linear discriminant analysis was used to validate FA data, 
however, lack of functionality in the Biotyper software prevented similar protein data analysis (the user 
was simply presented with an automated table of alphanumeric classifications accompanied by 
corresponding numerical score values).  Cross validation is a predictive statistical modeling technique for 
determination of class membership91.  It has been used extensively to validate complex datasets of mass 
spectra92.  CeO2 data was cross-validated to within 98% strain-level accuracy.  Correct strain-level ID CV 
was indicated by the numerical probabilities (high value = high probability) shown in grey for five 
replicates of each species.  The only incorrect classification occurred at the strain level with one replicate 
of A. baumannii AC54 classified as the other A. baumannii strain.  All replicates were validated to 100% 
at the species level. 
 Biotyper Protein Profiling 
      Protein-based Biotyper analysis of the same strains was conducted at the same time as FA-based 
MOLI MS on two separate MALDI instruments (Bruker Ultraflextreme and Microflex).  Protein results 
were reported as both alphanumeric results and numerical scores assigned to each sample by Bruker’s 
automated Real-Time Classification software.  These scores were based on a comparison of 
experimentally obtained spectra to Bruker’s Biotyper-specific database containing over 3000 profiles.  
Scores in the range of 2.300-3.000 provided a highly probable species ID.   Scores of 2.000-2.299 
indicated a “secure genus ID and probable species ID”; results in the range of 1.700-1.999 were classified 
as a probable genus ID and scores below 1.699 represented non-reliable ID.  All species were also 
analyzed using an ethanol/formic acid/acetonitrile pre-analysis extraction as suggested by the 
manufacturer for instances where ID was difficult or failed to yield results93.  We did not observe an 
improvement over conventional whole cell sample preparation.  Identities of all archived species used in 
this study were confirmed by 16S rRNA sequencing using universal primers that ensured coverage of all 
9 variable regions of the 16s rRNA gene, as previously described94-96. However, A. pittii and A. 
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nosocomialis, were only identified at the genus level and were thus cultured from newly obtained ATCC 
stocks and analyzed without passage. 
 Enterobacteriaceae ID  
      Protein profiling was conducted on five identical colonies of two strains each of E. coli, Salmonella, 
and Shigella.  Results are summarized in Table 3.1 and are presented as automatically generated in the 
Biotyper output reports.  Instances where Biotyper-derived alphanumeric results were not supported by 
concomitant numerical score values are indicated in grey with a brief explanation of each discrepancy in 
parentheses.  Two strains of E. coli were correctly identified by both protein profiling platforms.  All 
Salmonella numerical score values indicated species ID, however, the user was prompted by the Biotyper 
with a warning indicating these samples could only be accurately typed to the genus level.  Both Shigella 
species were misidentified as E. coli.  
      Confirmation of Ultraflextreme results was obtained for each species with analysis on a Microflex 
Biotyper (data not shown).  The Ultraflextreme is a more sophisticated instrument that was detuned as 
described in the Methods section by Bruker service engineers to match Microflex FDA-approved 
specifications for running the Biotyper software package.  While results were similar, some variation was 
observed across instrument platforms.  Of concern, numerous examples in Tables 3.1-3.3 demonstrate the 
tendency for the Biotyper to report alphanumeric species IDs that are supported only by genus numeric 
score values.  Such outcomes can most certainly result in confusion on the part of clinical technicians and 




Table 3.1. Ultraflextreme Biotyper Enterobacteriaceae ID. Score range: 2.30-3.00 = 'highly probable 





      Analyses of two separate strains of five different Acinetobacter species were conducted on both 
instruments.  Results are summarized in Table 3.2.  A. baumannii ATCC 17976 was either misidentified 
or no reliable ID was provided.  A. baumannii AC54 was identified to the species by Ultraflextreme 
analysis, while Microflex analysis gave genus level numeric score values with alphanumeric species ID.  
A. calcoaceticus 75.73 was misidentified by both protein platforms.   
      Both instrument platforms correctly identified all A. haemolyticus samples to the species with the 
exception of one replicate of each strain classified by the Ultraflextreme at the species with secure genus 
numeric score values.  Both A. pittii (formerly genomospecies 3)24 strains were correctly identified by the 
Ultraflextreme with ATCC 17922 given one secure genus, probable species numeric sore and 4 probable 
genus scores.  The Microflex system failed twice to provide any ID with the remaining replicates 
identified correctly with probable genus scores.  Both instruments identified A. pittii (formerly 
genomospecies 3)24 ATCC 19004.   
      The Ultraflextreme correctly identified A. nosocomialis (formerly genomospecies 13)24 ATCC 17903.  
The Microflex correctly identified it twice with secure genus ID, probable species numerical score values, 
but misidentified it three times as A. baumannii.  All five replicates of A. nosocomialis (formerly 
genomospecies 13)97 ATCC 700472 were misidentified by Ultraflextreme Biotyper as four different 
species.  The Microflex likewise misidentified this strain as three different species with A. haemolyticus 
as the only common misidentification between the two platforms.  Such repeated observation of 
automated species-level misidentification despite the fact that the Biotyper software gave genus only 
numerical score values is of concern because of potential misdiagnosis of human pathogens as closely-
related but less or non-virulent cousins.  Specifically, as an example, A. baumannii, a well-characterized 










      Comparative analyses of two separate strains of five different Listeria species (Table 3.3) were 
conducted using the Biotyper Listeria-specific database.  The Ultraflextreme platform identified L. 
monocytogenes ATCC 19115 once with a secure genus, probable species numerical score value.  The 
remaining four samples were misidentified as L. innocua.  Similarly, the Microflex system identified this 
strain twice to the species, but misidentified it three times as L. innocua.  
The Ultraflextreme Biotyper identified three replicates of L. monocytogenes ATCC 13932.  The two 
remaining samples were incorrectly identified as L. innocua.  In comparison, the Microflex correctly 
identified this strain four times but misidentified it once as L. innocua,   
      Again, automated alphanumeric species-level protein ID outputs were repeatedly observed with only 
secure genus numerical score values to support such outcomes.  This is problematic, especially when it 
concerns misidentifying a particularly dangerous food-borne pathogen such as L. monocytogenes as L. 
innocua, which is rarely associated with human disease in immunocompromised patients99,100.  This is 
perplexing given that Bruker has developed a Listeria-specific database explicitly for analysis of this 
genus.  
      Both platforms identified both L. grayi strains to the species level in all instances.  However, the 
Ultraflextreme assigned alphanumeric species ID to L. grayi subsp. grayi WSLC 6036 and L. grayi subsp. 
murrayi WSLC 6037 twice with secure genus, probable species numeric score values, and three times 
with only probable genus scores.  The Microflex system correctly identified all five replicates with secure 
genus ID, probable species ID numeric score values.   
      The Ultraflextreme platform identified three replicates of L. seeligeri WSLC 40126.  It also 
misidentified this strain once as L. welshimeri and failed once to provide any ID.  The Microflex Biotyper 
similarly correctly identified this strain twice but also misidentified it once as L. monocytogenes and twice 








       Both platforms identified L. seeligeri WSLC 40127 twice to the species level (the Ultraflextreme 
once with a secure genus, probable species numeric score value and once with only a probable genus 
score, the Microflex twice to the species but with only probable genus numeric score values).  Both also 
misidentified this strain twice as L. monocytogenes, and once as L. innocua. 
      L. welshimeri WSLC 50146 was alphanumerically identified four times to the species, twice with 
secure genus, probable species scores, and twice with genus only scores.  The Ultraflextreme failed to ID 
the fifth replicate.  The Microflex platform identified this strain four times to the species but with only 
probable genus scores.  L. welshimeri WSLC 50150 was identified by the Ultraflextreme in all five trails 
to the species, twice with secure genus, probable species numeric score values and three times with only 
probable genus values.  The Microflex platform identified this strain four times to the species (one secure 
genus, probable species score value, and three probable genus scores), and misidentified it once as L. 
monocytogenes.    
      Both instruments correctly identified L. innocua ATCC 33090.  The Ultraflextreme system 
misidentified L. ivanovii ATCC 19119 once as L. monocytogenes, and four times as L. innocua.  The 
Microflex platform had similar issues with this strain, misidentifying it four times as L. monocytogenes, 
and once as L. innocua. 
 Comparison of CeO2-catalyzed MOLI MS Fatty Acid and Protein Profiling Accuracy 
       A summary of comparative accuracies of CeO2-catalyzed MOLI MS results to those observed using 
both protein profiling platforms is shown in Table 3.4.  It should be noted that for the purposes of a strain-
by-strain comparison of FA profiling to protein profiling, the FA spectral database contained fewer 
entries than the commercial Bruker Biotyper library.  It is a possibility that as future work increases the 
size of the FA database, accuracy could be negatively impacted.   However, this is speculative at present 
and must be borne out by further work.  The percentages in Table 3.4 reflect the number of correct IDs in 
each category divided by the total number of samples in that category.  CeO2–catalyzed FA profiling gave 
100% correct ID at the genus and species level, while 3% (a single A. baumannii AC54 was misidentified 
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as an incorrect strain of the correct species and a single C. krusei was misidentified as an incorrect 
species. 
  
Table 3.4. Percent accuracy of Biotyper bacterial ID and CeO2-catalyzed MOLI fatty acid analysis. 
 
 
In contrast, for the four groups analyzed on protein profiling instruments, the Biotyper provided 67% 
(Ultraflextreme and Microflex analysis of Enterobacteriaceae) and 96% (Ultraflextreme analysis of 
Listeria) to 100% (Microflex analysis of Listeria) correct ID at the genus level.  High genus-level 
accuracy was expected for Listeria given the use of the Bruker Listeria genus-specific database.  
Accuracies ranging from 30% (Ultraflextreme analysis of Enterobacteriaceae) to 68% (Microflex 
analysis of Listeria) were observed at the species level.  Twenty-four percent (Ultraflextreme analysis of 
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Acinetobacter) to 33% (Microflex analysis of Enterobacteriaceae) were misidentified as an incorrect 
genus/species and a total Biotyper ID failure rate of 0-18% was observed across the entire study.   
       
 
 
Figure 3.2. Comparison of protein and CeO2-catalyzed fatty acid mass spectral profiling. 
 
Representative FA and protein spectra for bacteria that were misidentified by the Biotyper are shown in 
Figure 3.2.  Without knowledge of the proprietary Biotyper software architecture it is uncertain, but it 
appears that minor protein peaks are not considered and that the major peaks are too similar for a 
distinction to be made.  As examples, comparison of spectra of E. coli K12 and S. boydii ATCC 9207 
(Fig. 3.2a) showed the same four major protein peaks leading to the misidentification of S. boydii as E. 
coli.  Despite the fact that A. calcoaceticus 75.53 was misidentified as A. baumannii, comparison of the 
protein spectra for these two strains appear visually quite different (Fig. 3.2b).  The largest protein peaks 
in the spectra of L. monocytogenes ATCC 13932 and L. innocua ATCC 33090 (Fig. 3.2c) are nearly 
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identical, with only small differences in intensity.  In cases where correct assignments for other species 
were observed (data not shown), major differences were required in the protein distributions for correct 
ID. 
      Although the same major FAs are observed as the molecular weight minus a proton [M-H]-, in each of 
the representative FA spectra shown in Figure 3.2d-f, the relative peak intensities, as well as the presence 
of varying minor FAs, readily allowed for visual and statistical sample differentiation.  A specific 
example is seen in Figure 3.2e where A. baumannii is visually different than A. calcoaceticus because of 
the appearance of C19:0, C20:0, and C21:0 peaks, which were not observed in the latter. 
3.4. Discussion 
      We address a fundamental question currently surrounding MS-based bacterial ID: which bacterial 
analyte among a number of possible targets gives the highest possible clinical diagnostic accuracy using 
modern, commercial MALDI-TOF MS platforms.  More specifically, is there a bacterial biomarker with 
taxonomically useful properties that readily lends itself to rapid MALDI ID without confounding results 
due to the similarity of that biomolecule across closely related members of clinically important genera.  
The ideal MS diagnostic system should achieve rapid, accurate, reproducible results with minimal false 
ID, and do so using a relatively inexpensive, high-throughput, user-friendly assay.  This could be 
achieved by exploiting analytes whose expression and/or composition does not change appreciably in 
response to environmental conditions such as nutrient availability, temperature, or pH and that are present 
in sufficient amounts to allow detection.  It is widely acknowledged that expression of bacterial proteins 
and FAs (two of the most extensively exploited sources of taxonomic biomarkers for bacterial 
identification) can vary significantly in response to variations in environmental stimuli28, 29, 30.  It is for 
this reason that precise culturing methods have been developed and adopted for sample preparation for 
both FA and protein analysis.  By adhering to strict culturing practices (e. g. precise media formulation, 
carefully maintained incubation temperature, and consistent culture duration) such variations are easily 
minimized and standard operating procedures (SOPs) provided by diagnostic instrument manufacturers 
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have made reproducible sample preparation a matter of routine.  
     Current protein-based MALDI-TOF MS diagnostic instruments have recently experienced a rapid 
increase in clinical use with the Bruker Biotyper and bioMérieux VITEK MS platforms.  Both these 
systems draw on the tenants of protein-based bacterial differentiation first realized by Holland et al in the 
1990s31, 32.  While reasonably rapid and user friendly, we found that the Biotyper suffered from some 
fundamental drawbacks that limit its accuracy and overall utility.  Based on our results, and those of 
others,14, 15 it is clear that this system cannot differentiate closely related bacterial species that in many 
cases express very similar if not identical proteins with similar peak intensities14.  These problems often 
result in the reporting of incorrect IDs or failure to provide any reliable ID at all.  Most notably, this is 
borne out by the observation of the misidentification of virulent A. baumannii as the closely related, but 
less problematic, A. calcoaceticus (Table 2 and Supplementary Table 2).  Perhaps even more concerning 
was the observation of Biotyper misidentification of L. monocytogenes as rarely pathogenic L. innocua 
(Table 3 and Supplementary Table 3), which has the potential for significant negative clinical 
implications.   
     Despite the current commercial proliferation (manufacturers quote sales figures of several hundred 
units per year) of protein-based instruments, early studies pointed towards the potential of FA-based 
bacterial ID.  These investigations demonstrated that bacterial lipid composition successfully correlated to 
taxonomical trends based on extracted, derivatized FAs followed by gas chromatography (GC)33, 34, 35, 36, 
37.  Since the 1990s the commercial MIDI platform has been offered for FA methyl ester-based diagnostic 
ID, but has been limited by the time requirements of the assay38.   
     By coupling the catalytic activity of CeO2 with MALDI laser energy, it was observed that bacterial 
lipids decomposed into taxonomically useful FA constituents.  Novel CeO2-catalyzed MOLI MS allowed 
highly accurate ID of species that were routinely misidentified by the Biotyper.  Multivariate statistical 
analysis of the resulting spectra allowed for rapid, highly accurate strain-level ID and differentiation of 
Enterobacteriaceae, Acinetobacter, and Listeria.  Our FA analysis in comparison to the Biotyper 
provided higher resolution, with 98% accuracy at the strain level and 100% at the species level.  
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     In summary, we have shown by comparison of FA and protein profiling that CeO2-catalyzed MOLI MS 
offers a potentially powerful approach to bacterial ID.  We validated method accuracy with sound statistical 
procedures across a collection of clinically important species that are known to be difficult to differentiate 
by protein profiling.  The primary advantages of this new diagnostic technique are the avoidance of 
misidentification of closely related species; it has the potential to provide strain-level capabilities, and 
improve accuracy where current technologies often lack genus- or species-level ID capabilities.  Future 
work will be required to completely evaluate the full capabilities of the technology for bacterial ID and 
other lipid analyses, construct a comprehensive database, and further develop MOLI MS FA profiling as 






















CHAPTER 4  
STRAIN-LEVEL STAPHYLOCOCCUS DIFFERENTIATION BY CEO2-METAL OXIDE LASER 
IONIZATION MASS SPECTROMETRY FATTY ACID PROFILING 
Published manuscript from BMC Microbiology (Accepted Mar. 2016)1 
Nicholas Saichek2,3, Christopher Cox2, Seungki Kim4, Peter Harrington5, and Kent Voorhees2,6 
4.1. Introduction 
Staphylococci are Gram-positive facultative anaerobes comprising 44 species, which are commonly 
found in the soil or on the skin of birds and mammals117.  S. aureus is the most pathogenic of the genus 
and is commonly associated with septicemia, osteomyelitis, endocarditis, and skin infection118.  Isolates of 
S. aureus are generally susceptible to β-lactam antibiotics, but extensive use of this class of drugs has led 
to the increasing emergence of resistant mutants119.  In 2011 the Centers for Disease Control and 
Prevention (CDC) reported 80,461 methicillin-resistant S. aureus (MRSA) infections in the U.S. leading 
to 11,285 deaths.  While improved infection control policies decreased clinical MRSA infections by 52% 
between 2005 and 2011, there remains a need to rapidly screen patients for S. aureus and determine 
antibiotic resistance.   
      Culture-, biochemical-, and molecular-based methods are the current standard for clinical MRSA 
detection.  Culture methods offer high specificity, but relatively lengthy turnaround times (TAT) of 24-72 
h. and the requirement for secondary resistance testing contribute significantly to delays in initiation of 
treatment.  A retrospective cohort study of bloodstream infections found that mortality rates rose 7.6% per 
hour for every hour of delay in the initiation of effective antimicrobial therapy120.  Chromogenic agars 
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have been used to slightly decrease TAT to 18-24 h, while also improving specificity, but secondary 
resistance testing is still required121.   
     Some of the most common approaches for analysis of the specific chemical characteristics of 
staphylococci include:  coagulase activity, hemolysis, nitrate reduction, phosphatase, and aerobic acid 
production from sugars and carbohydrates122.  Kloos and coworkers reported a simplified scheme for 
analyzing the extensive data produced by biochemical results to characterize staphylococci.  The 
commercially available bioMerieux API STAPH-IDENT and American Hospital Supply Corporation 
MicroScan Systems are based on this approach.  The API Staph-IDENT utilizes a battery of 10 
microscale biochemical tests, whereas the MicroScan System consists of 27 tests123.  These systems were 
reported to have accuracies of 88% and 86.4%, respectively, but also showed inherent limitations124.  
Specifically, the API-STAPH-IDENT failed to identify phosphatase-negative S. epidermidis.  In 
comparison, while the MicroScan System correctly indentified S. epidermidis, it misidentified S. hominis, 
S. warneri, and S. sciuri.  In addition, biochemical tests that rely on coagulase or clumping-factor 
production also had inherent limitations.  These included a failure to differentiate between S. 
pseudintermedius and S. delphini and, to a greater extent, the misclassification of all coagulase-positive 
staphylococci as S. aureus125,126.  
      To address such limitations and improve specificity, molecular methods for analyzing specific genetic 
markers have been explored.  In an attempt to identify S. aureus and assay for methicillin resistance, 
multiplexed PCR has been used to simultaneously target the staphylococcal nuc gene, encoding a 
thermostable nuclease (TNase), and the mecA gene, encoding a penicillin binding protein127.  PCR results 
agreed with coagulase production and agar screening tests for single-step identification of MRSA.  In an 
attempt to identify coagulase-negative staphylococcal strains (CoNS), one study targeted a 429-bp 
amplicon of the sodA gene encoding the manganese-dependent superoxide dismutase128.  Clinical isolates 
and ATCC reference strains were identified with 83% accuracy in about 8 h.  While culturing and 
biochemical assays offer comparable specificity to results obtained by hsp60129 and 16S rRNA 
sequencing130, TAT is still typically greater than 24 h. 
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      Turnaround time was significantly reduced using phage amplification-based lateral flow 
immunochromatography (LFI) 131.  This work led to the FDA-approved MicroPhage KeyPath 
MRSA/MSSA blood culture test132.  Exploitation of S. aureus-specific phage amplification targeting 
clinical blood isolates allowed for simultaneous identification and methicillin resistance determination 
with a TAT of 5 h and 98.3% accuracy131.  
     Published reports suggest the rise of non-S. aureus infections in clinical studies, some with developed 
resistance to multiple classes of antibiotics133-135.  Indeed, CoNS are among the most commonly reported 
bloodstream isolates (37.3% compared to 12.6% for S. aureus) 136.  These reports place emphasis on the 
importance of infection by S. epidermidis, S. saprophyticus, S. lugdunensis, and S. schleiferi further 
demonstrating the need for more rapid techniques for simultaneous species-level Staphylococcus 
identification and antibiotic resistance determination.  Bacterial protein-profiling by matrix assisted laser 
desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) has been used to identify S. 
aureus and CoNS in prosthetic joint infections137.  Although this method was relatively rapid, only 52% 
highly probable species-level identification was obtained.  A report by Dubois and coworkers using the 
Bruker Biotyper MALDI-TOF MS protein analysis of 152 staphylococcal isolates correctly identify 151 
samples at the species level. These results confirmed their earlier findings using a PCR-based sodA gene 
array138.  Rajakurna et al. correctly identified a different set of Staphylococcus isolates using the Waters 
Corporation MicrobeLynx database, with 97% accuracy139.  
     A MALDI mass spectral-bacterial profiling approach using fatty acids as diagnostic biomarkers rather 
than proteins was recently reported140-142.  Employing MALDI with CeO2 (metal oxide laser ionization 
[MOLI] MS) as an in-situ saponification catalyst and matrix replacement, bacterial samples were 
identified to the species level with 97% accuracy143.  In a follow up study, suites of Enterobacteriaceae, 
Listeria, and Acinetobacter were analyzed in parallel by MOLI MS fatty acid profiling and the Bruker 
Biotyper protein profiling144.  The results from this study clearly established fatty acid MALDI profiling 
for strain-level differentiation of closely-related phylotypes with 98-100% accuracy.  Protein profiling of 
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the same samples correctly identified Enterobacteriaceae with 30%, Listeria with 64% and Acinetobacter 
with 66% accuracy at the species level.      
     The following paper describes MOLI MS CeO2 fatty acid profiling of 26 non-S. aureus strains and 10 
S. aureus strains (five MRSA and five MSSA).  A fuzzy rule building expert system (FuRES) 145 and a 
self-optimizing partial least squares discriminant analysis (PLS-DA) 146 were used for classification. 
4.2. Experimental Section 
 Bacterial Isolates 
      Table 4.1 summarizes the bacteria used in this study.  Staphylococcus strains were obtained from an 
in-house collection at CSM, JMI laboratories (North Liberty, IA) and the National Collection of Type 
Cultures (NCTC) (Salisbury, UK).  Bacteria were streaked on brain heart infusion (BHI) medium (BD-
Difco, Franklin Lakes, NJ) from cryogenic freezer stocks and cultured at 37oC for 18 h. as specified in 
Bruker standard operating procedures for bacterial cultivation.   
Table 4.1. Staphylococcus isolates used 
Species Strain 
A. Species-level study  
S. aureus ATCC 29213 
S. auricularis JMI 66-1339p 
S. capitis JMI 186-14645a 
S. epidermidis JMI s12410 
S. haemolyticus JMI 14138 
S. harmolyticus JMI s11298 
S. hominis JMI 9382 
S. hyicus JMI 15-8308a 
S. lentus JMI 7613 
S. lugdunensis JMI 112-3379a 
S. saprophyticus PTX-0652 
S. shleiferi JMI 100-1511a 
S. simulans JMI 7295 
S. warneri JMI 12019 
B. Strain-level study  
S. aureus ATCC 13150 
S. aureus ATCC 14775 
S. aureus NCTC 9315 
S. aureus NCTC 8292 
S. aureus NCTC 8321 
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Table 4.1. continued 
 
 
S. aureus NCTC 10023 
S. aureus JMI 105 
S. aureus CC 4051 
S. aureus CC 4083 
S. epidermidis PTX 0254 
S. epidermidis PTX 0260 
S. epidermidis PTX 0257 
S. epidermidis PTX 0255 
S. epidermidis PTX 210 
S. epidermidis PTX 0145 
S. epidermidis PTX 0385 
S. epidermidis PTX 0427 
S. epidermidis PTX 380 
S. hominis JMI 12008 
S. hominis JMI 2541 
S. hominis JMI 7922 
S. hominis JMI 10153 
S. hominis JMI 6983 
S. hominis JMI 6856 
S. hominis JMI 3655 
S. hominis JMI 3059 
S. hominis JMI 3143 
C. Resistance study  
S. aureus ATCC 13150 
S. aureus ATCC 14775 
S. aureus NCTC 9315 
S. aureus NCTC 8292 
S. aureus NCTC 8321 
S. aureus NCTC 10023 
S. aureus JMI 105 
S. aureus CC 4051 
S. aureus CC 4083 
S. aureus ATCC 49476* 
S. aureus CC 4002* 
S. aureus CC 4038* 
S. aureus CC 4045* 
S. aureus CC 4048* 
S. aureus CC 4049* 
S. aureus CC 4078* 
S. aureus CC 4086* 
S. aureus CC 4097* 




 Lipid Extraction 
       Lipids were extracted as previously described140,143.  Briefly, individual colonies were suspended in 
50 µL of a 1:2 v/v methanol/chloroform (Pharmco-AAPER, Shelbyville KY and Fischer, Pittsburgh PA, 
respectively) and vortexed for 120 s. to allow for cell disruption.  An equal volume of phosphate buffer 
saline (PBS) at a pH of 7.4 was added prior to additional vortexing to facilitate phase separation.  Extracts 
were centrifuged prior to MALDI sample preparation. 
 Mass Spectrometry 
       Sample preparation for MOLI MS analysis was carried out as previously described141.  Briefly, 100 
mg of CeO2 (Cermac Inc., Milwaukee, WI) was suspended in 1 mL of n-hexane (Sigma Aldrich) prior to 
spotting 1 µL of the resulting slurry on a standard Bruker stainless steel MALDI plate.  Two µL of each 
lipid extract was deposited directly on a CeO2 spot and allowed to air dry prior to analysis.  MOLI-MS 
measurements were performed with a Bruker Ultraflextreme MALDI-TOF MS (Bruker Daltronics, 
Billerica, MA) in negative-ion reflectron mode with a grid voltage of 50.3%, a delayed extraction time of 
120 ns, and a sampling frequency of 1 kHz on a 355 nm Nd:YAG laser.  Five replicates of each isolate 
were analyzed as 500 shot composites using automated laser rastering to ensure instrument stability. 
 Data Analysis 
      Mass spectra were exported as ASCII files and processed using a Python algorithm to select and 
centroid 24 specific fatty acid peaks (Table 4.2), and scale each peak to total ion intensity.  Processed data 
were written as .xls files for import into R (Ver. 3.0.2, R Foundation, Vienna, Austria) as a data frame.  
The prcomp()function  mean centered and calculated PCA scores before plotting with the built-in 
plot()function.  Leave-one-spectrum-out cross-validation (LOSOCV) was performed using linear 
discriminant analysis to validate the classification rate.  Processed fatty acid profiles were analyzed with 
MATLAB 2014a (Mathworks, Natick, MA).  Generalized prediction rates were measured using three 
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Latin partitions and 100 bootstraps145.  Two classifiers were evaluated:  a fuzzy rule-building expert 
system (FuRES) 145 and partial least squares discriminant analysis (PLS-DA) 146 
Table 4.2. Fatty acids used in Principal Component Analysis 































The PLS-DA algorithm used two Latin partitions and ten bootstraps to calculate average pooled 
prediction errors150.  The number of components (i.e., latent variables) that minimized error was selected 
and used to build a model from the set of training data, which was then used as a prediction set.  Training 
data consisted of a set of profiles used to build the classifiers; the test data was the set of profiles used to 
evaluate the performance of these classifiers.  Hierarchical cluster analysis was used to generate 
dendrograms and graphically illustrate linkage distances (Euclidean distances) obtained from an 
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agglomerative algorithm.  The distances were between pairs of profiles or between the averages of 
profiles from sub clusters. 
4.3. Results and Discussion 
 Spectral Analysis 
      MOLI MS was used to analyze 14 Staphylococcus extracts listed in Table 4.1A to develop fatty acid 
profiles.  For the 14 Staphylococcus species, the spectra (data not shown) contained similar fatty acids.  
C15:0 was common to all spectra as the base peak, while the other FAs ranged from 0-30% relative 
abundance.  The intensities of FA peak distribution allowed the spectra to be visually divided into three 
distinct categories: Group 1: S. aureus, S. auricularis, S. capitis, S. epidermidis, and S. shleiferi, which 
were all observed to have similar respective C16:0, C17:0 and C18:0 ratios; Group 2: S. harmolyticus, S. 
haemolyticus, S. hyicus, and S. saprophyticus, which displayed the highest prevalence of unsaturation 
consisting of 10-38% unsaturated FAs; and Group 3:  S. lugdunensis, S. lentus, S. simulans, and S. 
warneri, which each exhibited a unique defining characteristic absent from the other two groups.  Figure 
4.1 shows two representative spectra for each of the three groups.  As visual examples, slight differences 
in the relative abundance of minor FAs for Group 1 enhanced differentiation.   
      Figure 4.1A illustrates differentiation of S. aureus and S. auricularis by the appearance of C17:2 and 
C20:1 in the latter.  As shown in Figure 4.1B, minor FAs were crucial in separating Group 2 organisms.  
For example, S. haemolyticus was differentiated from S. saprophyticus by the absence of C20:0 as well as 
a decrease in C18:0 and increase in C18:1 in the latter.  Figure 4.1C illustrates the differentiation of 
Group 3 organisms.  S. lugdunensis, was distinguished from S. lentus by C14:0, which was the second 
most abundant FA with respect to C15:0, encompassing 20% of the relative abundance, as well as by the 
appearance of C21:0 in S. lentus.  Visual analysis of the respective ratios of FAs provided a qualitative 





Figure 4.1. Representative fatty acid profiles. Fatty acids are labeled with respect to chain length and 






      Principal component analysis (PCA) was employed to classify Staphylococcus at the species-level.  A 
score plot of the first three components, which encompassed 93.6% of total variance, is shown in Figure 
4.2.   
 
 
Figure 4.2. Species-level PCA differentiation of 14 Staphylococcus species. 
 
Colored points represent individual replicates of each bacterial species.  The degree of separation was 
indicated by the distinct clustering of members of the same species (inner variance) and the distance 
between different species (outer variance).  All species clearly plotted in unique space, which is supported 
by the 100% classification rate obtained by LOSOCV.  Figure 4.3 shows a dendrogram based on 







Figure 4.3. Dendrogramatic representation of Staphylococcus species differentiation.  Branch lengths 
were determined using average linkages and Euclidean distance. 
  
       The FuRES tree (Figure 4.4) defines 13 rules indicating perfect classification145.  Average prediction 
results for 100 bootstraps were 98.1 ± 0.3% for FuRES and 90.7 ± 0.3% for PLS-DA.   Bootstrap Latin 
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partition validation randomly divided the data into training and test sets such that the training set contained 
twice the number of data points when compared to the test set.   
 
Figure 4.4. FuRES species-level Staphylococcus classification tree.  Thirteen rules indicate perfect 
classification. 
 
In addition, validation maintained the same class distributions between training and test sets so that training 
and test sets would have the same proportion of objects from each class.  Three hundred models were built 
and evaluated for bootstrap analysis.  Because each profile was only used once per bootstrap, the results of 
three Latin partitions were pooled and are comprehensive for all FA profiles.  The results from 100 
bootstraps were averaged and reported with 95% confidence intervals.  This validation approach, which is 
much more rigorous than LOSOCV, is a weaker measure with respect to a model’s dependence on training 
set composition and the accuracy of the data within the prediction set.  
 Strain-level Differentiation 
       The versatility of MOLI MS for strain-level identification was further explored by analyzing extracts 
of 27 additional strains (Table 4.1B).  Figure 4.5 shows a score plot of the first two PCs for this data; a 
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total variance of 94.7 % was defined by the first two PCs.  The strains are denoted numerically with each 
species being represented by a different color. 
 
 
Figure 4.5. Strain-level PCA differentiation of 27 Staphylococcus isolates. 
 
Leave-one-spectrum-out cross-validation (LOSOCV) of the first ten PC scores correctly identified 100 % 
(145/145) of the samples at the species level and strain level, showing that all strains plotted 
independently.  Species-level groupings were also seen in the dendrogram in Figure 4.6, where each main 
branch point corresponded to its own individual species. FuRES and PLS-DA calculations correctly 
classified the data into 27 strains.  These results were obtained with 100 bootstraps and three Latin 
partitions. FuRES and PLS-DA had 93.9 ± 0.4 % and 84.1 ± 0.4 % prediction rates, respectively.  From 




Figure 4.6. Dendrogramatic representation of Staphylococcus strain differentiation. Branch lengths were 
determined using average linkages and Euclidean distance 
 
Susceptibility Determination 
      MALDI protein profiling methods have shown a series of characteristic peaks for identification of S. 
aureus147. From direct comparison of reference strains, discrimination between MSSA and MRSA was 
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achieved, but a uniform signature profile could not be identified to allow for unknown classification148.  
To assess the utility of MOLI MS FA profiling for antibiotic resistance profiling, 18 S. aureus strains 
(nine MRSA and nine MSSA), listed in Table 4.1C were analyzed.  A score plot of the first two 
components defining 97 % of the total variance is shown in Figure 4.7. In this projection, all strains were 
separated into unique groups according to methicillin resistance/susceptibility. Strain-level classification 
correctly identified 90/90 total replicates leading to 100 % accuracy using LOSOCV. 
 
 
Figure 4.7. PCA differentiation of MRSA and MSSA. MRSA strains are designated by dark blue and 
MSSA strains are light blue. 
 
The above data set yielded a FuRES tree with a single rule (figure not shown) indicating perfect 
separation of the two bacterial classes. Because each of the MRSA and MSSA groups comprised five 
replicates each of nine different strains, bootstrap Latin partitioning grouped all samples such that no 
profiles from any given strain were contained in both the training and prediction sets at the same time. 
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The prediction rates for strain-level identification of S. aureus were 94.7 ± 0.6 % for FuRES and 
93.7 ± 0.5 % for PLS-DA. FuRES discriminant weights, based on a 95 % confidence interval, for MRSA 
and MSSA classification revealed that odd-numbered fatty acids (C13, C17, C19, C21) were more 
prevalent in MSSA isolates, while even-numbered fatty acids (C14, C16, C18) were more prevalent in 
MRSA isolates (Figure 4.8). If the confidence interval intersected the origin in the positive or negative 
direction, that weight was significant. These results were in agreement with other reports in the literature 
that showed differences in FA composition between daptomycin-resistant Enterococcus strains149. 
      FuRES consistently outperformed PLS-DA, because it is a nonlinear classifier ideally suited for 
predicting classes that are binary encoded.  PLS, which is designed for calibration of continuous 
variables, may construct ill-conditioned models (ones with poor predictions) when trying to fit the binary 
encoded target matrix.  This problem often occurs with complex data sets150. 
 
 
Figure 4.8. Average of 300 FuRES discriminant weights with 95% confidence intervals.  Negative 




      We demonstrated the utility of CeO2-MOLI MS FA profiling coupled with multivariate statistical 
analysis for performing strain-level differentiation of various Staphylococcus species.  The emergence of 
MRSA and CoNS clinical isolates and the need for rapid clinical intervention has made it increasingly 
important to differentiate Staphylococcus isolates at the species and strain level.  LOSOCVs yielded 
accuracies of 100% and 96% at the species and strain level, respectively.  FuRES classification, with a 
more rigorous evaluation, also consistently achieved 98% accuracy.  Preliminary analysis differentiating 
MRSA from MSSA demonstrated the feasibility of simultaneously determining strain identification and 
antibiotic resistance, which is increasingly important for therapeutic management and infection control.  
Ultimately, as is also the case in protein profiling, construction of a comprehensive database will be 
important for identification of unknown isolates. 
       
















CHAPTER 5  
RAPID BURKHOLDERIA PSEUDOMALLEI IDENTIFICATION AND ANTIBIOTIC 
RESISTANCE DETERMINATION BY BACTERIOPHAGE AMPLIFICATION  
AND MALDI-TOF MS 
Published manuscript from Bacteriophage (Accepted Apr. 2014)1 
Christopher Cox2, Nicholas Saichek2,3, Herbert Schweizer4, and Kent Voorhees2,5 
5.1. Introduction 
      Burkholderia pseudomallei is an aerobic, saprophytic Gram-negative bacillus endemic to Southeast 
Asia and northern Australia but is increasingly found in other parts of the world151,152.  It is the etiologic 
agent of melioidosis, a debilitating disease of humans and animals, with a mortality rate of 20-50% in 
endemic regions151-154.  Disease manifestations range widely from acute localized septic infection to 
severe pneumonia, neurologic impairment, and disseminated septicemia to asymptomatic disease152,154.  
The Centers for Disease Control and Prevention has categorized B. pseudomallei as a Tier 1 select agent.  
Melioidosis is difficult to treat due to acquired and intrinsic antibiotic resistance155-157.  Because of this, a 
protracted regimen consisting of a 10- to 14-day intensive phase of intravenous ceftazidime followed by a 
three-month eradication phase of oral co-trimoxazole is the current recommendation for treatment of 
melioidosis155,156,158.  Several recent reports from around the world suggest that although still rare, the 
number of ceftazidime resistant B. pseudomallei infections may be on the rise159-163.   
      The increasing occurrence of antibiotic resistant infections has led to the need for more rapid methods 
of bacterial identification and antibiotic resistance determination in order to provide efficacious therapy.  
Culturing and disk diffusion assays are presently the standard for identification (ID) and antimicrobial 
susceptibility testing, but these methods are laborious and time-consuming, taking upwards of 72 h to 
                                                          
1 Reproduced with permission from: Bacteriophage. 2014, 4(3), e29011. 
2 Department of Chemistry, Colorado School of Mines, Golden, Colorado 80401, United States 
3 Graduate student and primary researcher 
4 Center for Intelligent Chemical Instrumentation, Ohio University, Athens, Ohio 45701, United States 
5 Corresponding author 
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complete155,156.  Furthermore, some ceftazidime resistant clinical isolates grow poorly on standard media 
and thus take even longer to culture and identify160.  MALDI-TOF MS has proven useful for bacterial 
detection and ID and is widely accepted in a growing number of clinical and industrial laboratories164-166.  
Two commercially available MALDI-TOF MS protein profiling instruments, the Bruker Microflex 
Biotyper and Biomérieux VITEK MS, have been approved by the U.S. Food and Drug Administration 
(FDA) for clinical bacterial ID.  However, while promising with regards to bacterial ID and relatively 
rapid testing times in the 24-48 h range, these units currently do not provide antibiotic resistance profiling 
capabilities.  There are limited recent reports on the use of the Biotyper in combination with secondary 
methods for antibiotic resistance determination.  Bruker has described a culture-based hydrolysis assay 
(Bruker Biotyper Spectrum Beta Lactamase) for Gram-negative β-lactam resistance determination 167,168 
and is experimenting with the use of stable isotope labeling of target strains prior to Biotyper analysis for 
differentiation of methicillin resistant Staphylococcus aureus169.  In contrast, in this report we demonstrate 
the application of phage amplification-based MALDI-TOF MS as a single method for simultaneous 
bacterial ID and antibiotic resistance determination.  Phages have been used for decades for bacterial 
identification170-174 and methods for combining phage amplification with the capabilities of MALDI-TOF 
MS have been reported for sensitive bacterial detection in the 1 to 4 h range175,176.  In this report, we 
extend the utility of MALDI-TOF MS by demonstrating its use not only for Burkholderia ID, but also for 
simultaneous antibiotic resistance determination using the previously described broadly infective B. 
pseudomallei phage X216177. 
5.2. Experimental Section 
 Bacterial Strains and Growth Conditions  
      B. pseudomallei Bp82 and Bp82.3, which are attenuated, select agent excluded ΔpurM derivatives of 
B. pseudomallei strain 1026b, were grown under BLS2 conditions as described previously178,179.  Stains 
were either cultured overnight at 37°C with continuous aeration in Luria Bertani (LB) broth (BD-Difco, 
Franklin Lakes, NJ) with the addition of 80 g/mL adenine or streaked onto LB-adenine agar. 
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 Phage Propagation and Purification 
      X216 phage stocks were obtained by liquid lysis of B. pseudomallei Bp82 at 37oC in LB-adenine 
medium at a multiplicity of infection (MOI) of 0.5, as previously described177,180.  Lysates were 
centrifuged at 12,000 x g for 20 min at 4oC to pellet bacterial debris.  Supernatants were filtered-sterilized 
using 0.22 μm low-protein binding polyether sulfone filters (Nalgene, Rochester, NY).  Phage particles 
were purified by polyethylene glycol (PEG)(8000 molecular weight) precipitation as previously 
described181 with the following modifications: 20 mL of crude lysate were mixed with a 20% w/v PEG 
solution containing 1.76 M NaCl and incubated overnight at 4oC with continuous inversion.  Precipitated 
phage particles were collected by centrifugation at 14,000 x g for 15 min at 4oC.  Resulting pellets were 
resuspended in 1 mL SM buffer (100 mM NaCl, 8 mM MgSO4, 50 mM Tris-HCl, pH 7.4) 182, re-filtered, 
titered by spot titer assay180, and stored at 4oC. 
 Determination of Burst Size and Time 
      The X216 burst size and time were determined by generation of one-step growth curves as described 
previously180.  Briefly, mid-log phase cultures of B. pseudomallei Bp82 (1.0 x 108 cfu/mL) were 
inoculated with X216 at an MOI of 0.005 and monitored by spot titer assay.  Triplicate samples were 
taken at 20-min intervals beginning at the onset of infection over 180 min and 10 L aliquots were 
spotted onto Bp82 lawns on LB adenine agar.  Plates were incubated overnight at 37oC.  Plaques were 
counted at each time point as described183 and the burst size determined by dividing the resulting phage 
concentration values by the initial concentration for one cycle of amplification. Burst time was likewise 
taken after one cycle of amplification.   
 MALDI-TOF MS 
      Samples were prepared for MALDI-TOF MS as previously described184.  Briefly, 10 L sample 
aliquots were treated with 2 µL of neat β-mercaptoethanol (BME) (Sigma, Saint Louis, MO) for 15 min at 
room temperature prior to analysis.  One microliter of ferulic acid matrix (15 mg/mL) (Sigma) in a formic 
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acid (Sigma), acetonitrile (Sigma), and de-ionized water mixture was then applied to a polished stainless-
steel sample plate (Bruker) followed by addition of 1 µL of treated sample and 1 µL of additional matrix 
in a sandwich fashion.  Sample spots were allowed to air dry before MALDI-TOF MS analysis. 
      Mass spectrometric measurements were made with a Bruker Ultraflextreme MALDI-TOF mass 
spectrometer (Bruker Daltonics, Billerica, MA) equipped with a 355 nm Nd:YAG laser. Measurements 
were taken in reflector mode with a grid voltage of 50.3%, a delayed extraction time of 120 ns, and low 
mass cutoffs of 5 kDa and 15 kDa for bacterial and phage analyses, respectively.  Three replicate spectra 
were collected for each analysis as 500 shot composites at a sampling frequency of 1 kHz using 
automated laser rastering.   
 Determination of MALDI-TOF MS Limit of Detection 
       To determine the limit of MALDI-TOF MS X216 detection, B. pseudomallei ID, and antibiotic-
resistance differentiation studies, 10-fold serial dilutions in phosphate buffered saline (PBS, pH 7.4) of a 
high-titer (3.0 x109 pfu/mL) PEG-purified phage stock were assayed by MALDI-TOF MS.  The lowest 
dilution that produced a X216 protein spectra was considered as the limit of detection.   
 In Silico Prediction of Phage Amplification 
      In silico estimation of the time during a X216 infection when phage concentrations would surpass 
the MALDI-TOF MS detection threshold was conducted using a phage therapy prediction algorithm176.  
Table 5.1. In silico X216 amplification modeling parameters.  
 
 
 1 Parameter Description Experimental values 
a Uninfected bacterial replication rate 1.0 at 37oC 
b Transmission coefficient  
(Measure of phage binding efficiency) 
1 x 10-7 
L Burst size 160 
k Lysis rate 1.5 
xi Initial uninfected bacterial 
concentration 
3.2 x 105 cfu/mL 
vi Initial infecting phage concentration 1.6 x 105 pfu/mL 
m Phage decay rate 0 
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ID and Differentiation of Drug-Sensitive and Resistant B. pseudomallei 
      For bacterial identification and antibiotic resistance determination, ceftazidime-susceptible ΔpurM 
strain Bp82 and its resistant PenA C69Y mutant derivative Bp82.3178 were subjected to phage infection 
and amplification using X216.  Strains were grown in LB + adenine at 37oC with or without the addition 
of 10 g/mL ceftazidime (Sigma) to an optical density (OD620nm) of 0.17, which corresponded to an 
approximate bacterial concentration of 1.0 x 108 cfu/mL.  Cultures were next back diluted to 3.2 x 105 
cfu/mL in fresh LB adenine and infected with 1.6 x 105 pfu/mL X216 (MOI 0.5).  Aliquots of each 
infected culture were assayed by MALDI-TOF MS with spectra obtained every hour for 3 h.  Results 
were confirmed by plaque assay. 
5.3. Results and Discussion 
 MALDI-TOF MS Detection of Phage Amplification as a Means of B. pseudomallei ID 
      MALDI-TOF MS analyses of B. pseudomallei (Fig. 5.1A) resulted in spectra displaying a myriad of 
small bacterial proteins in a mass range from 5 to 50 kDa.  In comparison, the X216 spectrum shown in 
Figure 5.1B contained only 3 peaks:  a 37.6 kDa peak corresponding to the phage major capsid protein, its 
doubly charged ion at 18.8 kDa, and the phage tail protein at 22.1 kDa.   
      These masses were in agreement with our previously published report describing the isolation, 
characterization, genome sequencing and annotation of X216177.  The MALDI-TOF MS X216 limit of 
detection was determined to be 2.6 x 107 pfu/mL.  Based on this data, all subsequent phage amplification 
reactions were initiated with concentrations below this value in order to only detect phage proteins 
resulting from amplification (rather than those from input phage used to initiate infection).  Spectra were 
taken at the onset of X216 infection of B. pseudomallei Bp82 at bacterial and phage concentrations 
below the MALDI-TOF MS limit of detection (3.2 x 105 cfu/mL, and 1.6 x 105 pfu/mL, respectively).  
Immediately following infection, as anticipated, no discernable signal was observed for either analyte 
(Fig. 1C).  As shown in Fig. 1D, once phage amplification proceeded and X216 virions were released 
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during cell lysis, a peak at 37.6 kDa was observed within 2 h that served as a secondary biomarker for the 
presence of B. pseudomallei.  Results were similar for identical experiments conducted with B. 
pseudomallei Bp82.3 (not shown). 
 
 
Figure 5.1. MALDI-TOF MS spectra of A) B. pseudomallei Bp82, B) phage X216, C) at onset of X216 
infection, and D) 2 h. post infection. Masses are indicated in kDa. 
 
 Determination of X216 burst size 
      One-step growth curves (Fig. 5.2) showed that X216 had an approximate burst size of 160 pfu per 
infected cell in B. pseudomallei Bp82 and a burst time of 150 min.  Results were identical with B. 
pseudomallei Bp82.3 (not shown).  This burst is slightly higher than the previously reported value of 120 
pfu per infected cell177.  However, burst size was previously determined using B. mallei ATCC23344 as a 




Figure 5.2. X216 one-step growth curve for determination of burst size and time during infection of B. 
pseudomallei Bp82. 
 
 In Silico Prediction of X216 Amplification-based MALDI-TOF MS Signal Detection 
       In order to detect only progeny phage resulting from the presence of the bacterial target of interest (as 
opposed to detection of the input phage used to start an infection), it was necessary to initiate 
amplification at a phage concentration below the limit of detection.  To address this and significantly 
reduce the labor and time for repeated preparation and analysis, the previously described method for in 
silico modeling176 was used to predict the time during X216 infection of B. pseudomallei when a 
detectable MALDI-TOF MS signal would first be achieved. 
 
Figure 5.3. In silico prediction of X216 amplification in B. pseudomallei. Dashed line: MALDI-TOF MS 
limit of phage detection 
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The MALDI-TOF MS X216 limit of detection (2.6 x 107 pfu/mL) is indicated in Figure 5.3 by a dashed 
line.  Based on this value, an input X216 concentration (vi) of 1.6 x 105 pfu/mL (well below instrument 
limit of detection) was used to infect B. pseudomallei at an initial concentration (xi) of 3.2 x 105
 cfu/ml 
(MOI = 0.5).  All parameters used in the algorithm are given in Table 1.   As shown in Fig. 1D, a X216 
burst, exemplified by the appearance of the 37.6 kDa major capsid protein peak, was observable within 2 
h of phage amplification.  The corresponding in silico model (Fig. 5.3) accurately predicted that phage 
concentrations would surpass instrument limit of detection within 2 h.  This calculation eliminated the 
need to collect and prepare aliquots prior to 2 h post infection. 
Phage Amplification and MALDI-TOF MS for Simultaneous Antibiotic Resistance Determination 
      With the increasing occurrence of antibiotic resistant bacterial infections, it is often critical to the 
success of treatment and patient survival to quickly identify a suspected pathogen and determine its 
antibiotic resistance profile.  Previous reports identified clinical B. pseudomallei strains harboring a C69Y 
substitution in the chromosomal penA gene encoding a putative twin arginine translocase (TAT)-secreted 
β-lactamase that conveyed high-level ceftazidime resistance163.  Rholl et. al constructed a B. pseudomallei 
Bp82 mutant derivative that carried the PenA C69Y mutation and found that this not only increased 
ceftazidime resistance greater than 85-fold, but also sensitized mutants to other β-lactams including 
amoxicillin, ampicillin, carbenicillin, and imipenem179.  This made the Bp82-Bp82.3 isogenetic strain pair 
ideally suited for BSL2 studies investigating X216 amplification-based Burkholderia ID in the same 
host background with and without exposure to ceftazidime.  By exploiting the species-specificity of phage 
amplification and its natural reliance on a viable host185, it was hypothesized that MALDI-TOF MS 
analysis for the appearance of a X216-specific protein profile both with and without the addition of 
ceftazidime could serve to simultaneously ID and differentiate sensitive and resistant strains using a 
single technique; this effectively eliminated one day of testing time in comparison to current methods.   
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       Figure 5.4 shows the results of a 3-h X216 infection of ceftazidime-sensitive B. pseudomallei Bp82 
without the addition of the antibiotic.  A major capsid peak was clearly observed within 2 h of the onset 
of phage infection (Fig. 5.4A). 
 
Figure 5.4. MALDI-TOF MS spectra of X216 amplification in ceftazidime-susceptible B. pseudomallei 
Bp82 with A) no addition of antibiotic, B) addition of 10 µg/mL ceftazidime, C) ceftazidime-resistant 
strain Bp82.3 with 10 µg/mL ceftazidime. 
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In contrast, as shown by the lack of a capsid protein peak at 37.6 kDa at any of the four time points shown 
in Figure 5.4B, the addition of ceftazidime at a concentration of 10 g/mL killed the susceptible strain 
and therefore precluded phage amplification.  In comparison, as shown in Figure 5.4C, phage 
amplification was detected during X216 infection of isogenetic resistant mutant B. pseudomallei strain 
Bp82.3, even when amplification reactions were treated with 10 g/mL ceftazidime.  Taken together, the 
data in Figure 5.4 clearly indicate the capability of phage amplification, detected by MALDI-TOF MS, 
for rapid and definite ID of B. pseudomallei and simultaneous antibiotic resistance determination.  By this 
method and using a typical 96 to 384 well MALDI-TOF MS target plate, high throughput analysis of 
multiple parallel phage amplification reactions can be used to effectively assay a large collection of 
antibiotics of interest and determine the resistance profile.   
      In addition to its utility for B. pseudomallei ID, X216 lyses 100% (9/9) of B. mallei strains tested177 
and although not explicitly assessed in this study, the described approach should also be applicable for 
identification of B. mallei.  Phage resistance in some strains is a notable caveat to the application of phage 
amplification for identification and antibiotic resistance determination.  Although X216 only infected 
78% of B. pseudomallei strains tested, it has one of the broadest ranges of infectivity for a single 
Burkholderia phage177.  To cover any remaining subset of resistant strains, one or more additional phages 
that infect these organisms must be isolated and characterized.  B. pseudomallei phages are readily found 
in soil samples from endemic regions186,187.          
5.4. Conclusion 
We conclude that MALDI-TOF MS combined with phage amplification is a rapid, sensitive, and 
reproducibly predictable approach for protein-based bacterial ID and simultaneous antibiotic resistance 
determination.  This method could be utilized with existing clinical and industrial MALDI-TOF MS 
systems such as the FDA approved Bruker Biotyper and Biomérieux VITEK MS, which are already in 
place in a growing number of laboratories.  This method offers two new capabilities to conventional 
MALDI-TOF MS-based bacterial ID assays.  First, phage amplification affords a significant increase in 
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sensitivity and reduction in ID testing time.  Also, by exploiting the reliance of phages on the presence of 
a viable host, phage-based MALDI-TOF MS provides the capability to simultaneously assay for bacterial 
antibiotic resistance.  Currently available commercial MALDI-TOF MS-based systems do not have this 
capacity, but could directly benefit from the incorporation of phage amplification methods, which can be 



























CHAPTER 6  
SIMULTANEOUS IDENTIFICATION AND ANTIMICROBIAL RESISTANCE 
DETERMINATION OF PATHOGENIC ENTEROCOCCI BY PHAGE-BASED MALDI-TOF MS 
Submitted manuscript to Clinical Mass Spectrometry (submitted Oct. 2017) 
Nicholas Saichek1,2, Christopher Cox1, and Kent Voorhees1,3 
6.1. Introduction 
      Enterococcus is a highly adapted genus capable of living in complex environments with harsh 
conditions, commonly inhabiting the gastrointestinal tract of animals and humans.  Enterococcus faecalis 
and faecium isolates, as a major cause of nosocomial infections including bacteremia and endocarditis, 
have become increasingly prevalent 189,190.  Due to the broad application of antibiotics over the years, 
Enterococcus isolates have developed increased resistance to multiple classes of antibiotics, including 
glycopeptides such as vancomycin, which was once considered the last line of defense 191,192.  
Vancomycin-resistant Enterococcus (VRE) is the second leading cause of hospital-acquired bacteremia 
193.  Even in cases where the source of the infection is known, enterococcal bacteremia results in mortality 
rates of 26% to 46%; cases dealing specifically with E. faecalis resulted in 32% mortality rates 194,195.  
Enterococci possess both intrinsic and acquired resistance to antibiotics.  Resistant strains express altered 
peptidoglycan precursors, replacing the alanine termini with either a lactate or serine which prevents 
binding of vancomycin.  These altered precursors still serve as substrates for cell wall biosynthetic 
enzymes to construct a peptidoglycan layer like their unaltered counterparts 196,197.  Acquired resistance to 
vancomycin often accompanies intrinsic resistance to other commonly administered antibiotics such as 
ampicillin and aminoglycosides, thus limiting the options for effective treatment 198.  
Enterococcal vancomycin resistance is classified into five phenotypes: vanA, vanB, vanC, vanD, and 
vanE 199; the most prevalent phenotypes being vanA, vanB, and vanC.  Most common, vanA, exhibits 
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high-level resistance to glycopeptide antibiotics vancomycin and teicoplanin, whereas vanB isolates are 
susceptible to teicoplanin.  VanC isolates possess low-level chromosomal resistance to vancomycin 200.  
The increasing incidence of multidrug resistance in E. faecalis and E. faecium has created an 
economic burden on the healthcare system.  The costs due to hospitalization, diagnostic testing, treatment, 
and infection control for antibiotic-resistant Enterococcus infections result in an increase of $16,000-
61,000 more per patient compared to antibiotic-susceptible infections 201-203.  A report by the National 
Healthcare Safety Network found that approximately 40% of device-associated infections in intensive 
care units were due to Enterococcus; E. faecalis was the source of 46% of those cases 193.  E. faecium was 
the second most predominant encompassing 30%.  Because of this, Enterococcus is listed by the 
Infectious Disease Society of America (IDSA) as a crucial pathogen for which new identification methods 
are urgently needed 204,205.  Current methods for Enterococcus spp. identification are primarily comprised 
of phenotypic culture-based characterization, DNA isolation/amplification, or genomic sequencing, all of 
which are too time-intensive and high-cost for high-throughput diagnostic testing.  Outside of the clinical 
laboratory, 16S rDNA sequencing is successfully used for taxonomic classification of Enterococcus spp., 
but this method is not tractable for routine applications 206-208.  
Phage amplification is an attractive potential for addressing these diagnostic shortcomings.  Phages 
have been used in the typing of bacterial pathogens for a century.  The first phage-typing techniques 
involved observation of plaques after infection of a bacterial lawn.  During propagation a bacteriophage 
infects a bacterial host with its genetic material and uses the cell machinery to produce progeny phage, 
resulting in cell lysis and release of progeny phage into the surrounding area.  Since phages rely on a 
viable host for propagation and because they are reliably species-specific, phage amplification has been 
applied to methods utilizing lateral flow immunochromatography (LFI) and matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI MS) for simultaneous bacterial ID and antibiotic 
resistance 209-213.  Phage amplification can be used to determine the resistance profile of isolates because 
growth of susceptible strains does not occur or is significantly inhibited by exposure to any given drug, 
precluding phage amplification.  Employing phage amplification coupled with MALDI-TOF MS has 
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reduced the overall time to diagnosis from hours rather than days.  The acidic conditions required for 
MALDI-TOF MS sample preparation, a result of the matrix and solvent, aid in the disassembly of some 
phages but has proven insufficient for breaking apart the capsid assembly of other phages 214.  Attempts to 
further disrupt the capsid proteins for MALDI MS analysis through reduction of disulfide bonds and 
sonication steps have been implemented, but still lack the harsh conditions necessary to reproducibly 
disassemble some bacteriophage 214,215. 
To effectively overcome this phage detection problem, other groups added a digestion step prior to 
liquid chromatography-mass spectrometry (LC-MS) analysis 216.  Specifically, tryptic peptides derived 
from amplified bacteriophage K were analyzed to determine if Staphylococcus aureus was resistant to 
cefoxitin and clindamycin 217.  This method involved solubilization of the phage with cleavable Rapigest 
surfactant along with spin filtration through size exclusion columns, followed by sample desalting with 
ion exchange chromatography prior to MALDI-TOF MS analysis.  Although this helped with removal of 
excess bacterial proteins and salts, due to the extensive materials used for sample cleanup and 
concentration, it is not suitable for implementation into clinical laboratories.    
This paper describes a high-throughput, phage-based MALDI-TOF MS approach involving trypsin 
digestion of phage proteins for detection of E. faecalis.  Isolated E. faecalis phages were evaluated for 
their wide host range infectivity against antibiotic-resistant and -susceptible E. faecalis.  The application 
of phage amplification coupled with protein digestion utilizing a new one-pot gradient method has been 
successfully implemented with MALDI-TOF MS without the inconsistent results of other disruption 
methods.     
6.2. Experimental Section 
 Bacterial Strains and Susceptibility Determination 
      Fifty Enterococcus strains, shown in Table 6.1 were grown O/N at 37oC prior to streaking on Mueller-
Hinton agar.  Antibiotic resistance screening was done by disk diffusion.  Briefly, vancomycin disks 
(Sensi-disc, Becton Dickinson BBL) (30 µg) were applied to the bacterial lawns and incubated for 18 hrs 
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at 37oC.  Strains were evaluated and reported as susceptible, intermediate, or resistant according to 
NCCLS performance standards218.   
Table 6.1. Bacterial strains used for infectivity studies 
Species Strain Susceptibility    
E. faecalis T4 VSE 
E. faecalis T6 VSE 
E. faecalis T7 VSE 
E. faecalis T8 VSE 
E. faecalis T11 VSE 
E. faecalis T12 I-VRE 
E. faecalis HIP11704 VRE (VanA) 
E. faecalis CH19 VSE 
E. faecalis B-4-111 I-VRE 
E. faecalis CH570 I-VRE 
E. faecalis Y16-1 VSE 
E. faecalis 79-3 VRE (VanB) 
E. faecalis 599951 VRE (VanB) 
E. faecalis Ned10 I-VRE 
E. faecalis D6 VSE 
E. faecalis HH22 VSE 
E. faecalis RM4679 VSE 
E. faecalis E1Sol VSE 
E. faecalis ATCC35038 VSE 
E. faecalis Merz96 VRE (VanB) 
E. faecalis Merz151 VRE (VanA) 
E. faecalis SF100 I-VRE 
E. faecalis SF350 VSE 
80 
 
   
E. faecalis SF21520 VRE (VanA) 
E. faecalis SF21521 VRE (VanA) 
E. faecalis SF24397 I-VRE 
E. faecalis SF24413 VRE (VanB) 
E. faecalis SF26630 VRE (VanB) 
E. faecalis SF28073 VRE (VanA) 
E. faecalis UAA943 VRE (VanA) 
E. faecalis 2924 VRE (VanA) 
E. faecalis 182970 VRE (VanA) 
E. faecalis UAA702 VRE (VanA) 
E. faecalis UAA769 VRE (VanA) 
E. faecalis UAA902 VRE (VanA) 
E. faecalis UAA1014 VRE (VanA) 
E. faecalis UAA1180 VRE (VanA) 
E. faecalis UAA1489 VRE (VanA) 
E. faecalis B84847 VSE 
E. faecalis UAA409 VRE (VanA) 
E. faecalis MMH594 VRE (VanB) 
E. faecalis V583 VRE (VanB) 
E. faecalis JH2SS VSE 
E. faecalis FA2-2 VSE 
 
If a plate exhibited a clearing zone of less than 9mm that strain was considered resistant (VRE); if the 
zone of clearance was greater than 12mm it was considered susceptible (VSE); if the zone was 9-12mm it 
was considered intermediately resistant (I-VRE).  Van type is indicated for resistant strains in Table 6.1. 
Broth dilutions of 1 µg/mL, 3 µg/mL, 5 µg/mL, 10 µg/mL, and 15 µg/mL were performed with 
Table 6.1 continued 
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vancomycin to determine the minimum inhibitory concentration (MIC) for resistant strains; 5µg/mL of 
vancomycin was chosen to be a suitable concentration for amplification studies.  A phage cocktail 
comprised of equal amounts of ϕ31, ϕ46, and ϕ51 was inoculated with E. faecalis MMH594 to ensure 
amplification of ϕ51 was not inhibited by other phages. 
Method Development and Comparison 
      Three currently used methods for trypsin digestion of proteins: the methanol method 219, the 
dithiothreitol method 220, and the conventional method 221, were slightly modified to increase digestion 
efficiency.  The modified methanol method consisted of boiling one µL of protein (0.2 µg/µL) with one 
µL of methanol for 10 min prior to addition of 1.5 µL trypsin (1 µg/µL) for digestion at 52oC for 5 min; 
the dithiothreitol (DTT) method consisted of microwaving a 1:1:1 (v/v/v) mixture of 10mM dithiothreitol 
in 25mM ammonium bicarbonate, pH 7.8, protein (0.2µg/µL), and trypsin for one minute at 800W; and 
for the conventional approach, two µL protein in 10uL 6M urea was incubated for 30 min before the 
solution was diluted with 25mM ammonium bicarbonate to 1M urea and overnight digestion with trypsin 
at 37oC.  As an alternative to the bottom-up approach of digestion, a previously utilized phage disruption 
method involving acid pretreatment and disulfide bond disruption with β-mercaptoethanol (βME) was 
applied to the Enterococcus phages as described 209,214.  Bovine serum albumin (BSA) was used as a 
protein standard to measure the digestion efficiency of β-mercaptoethanol (βME), (tris(2-
carboxyethyl)phosphine (TCEP), and urea during optimization.  After optimizing the conditions for 
protein digestion, a one-pot gradient method mixing one µL of phage with one µL of 1.5M urea in 50mM 
ammonium bicarbonate buffer pH 7.8 and 1.5 µL of trypsin at 1.0 µg/µL was developed.  Once mixed, 
the solution was incubated for 10 min ramping at 0.8oC/min from 48 to 55oC followed by cooling the 
sample to 37oC prior to MALDI-TOF MS.  The limit of detection for phage digestion analysis was 
determined by analyzing 10-fold serial dilutions of filtered lysates.   
Phage Amplification Studies and Antibiotic Resistance Determination 
      Three isolated bacteriophages, ϕ31, ϕ46, and ϕ51 were screened by plaque assay against the 50 E. 
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faecalis strains listed in Table 6.1 to determine their host range and infectivity rate (Carlson, 2005).  
Phages were considered lytic if any plaques were observed.  Phage stocks (~108 pfu/mL) were generated 
by incubating the phage of interest with the determined host(s) O/N at 37oC.  Parallel antibiotic 
susceptibility studies were performed in broth with and without 5 µg/mL vancomycin until the back-
diluted cultures reached an optimal OD620 of 0.3.  The cultures were subsequently diluted and phages 
were added to a final multiplicity of infection (MOI) of 0.1 followed by incubation for 6 hrs at 37oC.  
Resulting samples were centrifuged briefly and filtered through a 0.22 µm filter to remove bacterial 
debris.  The filtrates were then digested using the one-pot gradient method prior to MALDI-TOF MS 
analysis.    
MALDI MS Analysis 
Five microliters of alpha-cyano-4-hydroxycinnamic acid matrix (15 mg/mL) (Sigma Aldrich) in a 
50/50 solution of acetonitrile (Sigma Aldrich) and deionized water were mixed with trypsin-digested 
phage samples. One microliter was applied to a polished stainless-steel sample plate (Bruker Daltonics).  
Sample spots were allowed to air dry before MALDI-TOF MS analysis.  Mass spectrometric 
measurements were made with a Bruker Ultraflextreme MALDI-TOF MS (Bruker Daltonics) equipped 
with a 355 nm Nd:YAG laser. Measurements were taken in reflector mode with a grid voltage of 50.3%, a 
delayed extraction time of 120 ns, and low mass cutoffs of 700 Da for phage digest analysis. Three 
replicate spectra were collected for each analysis as 500 shot composites at a sampling frequency of 1kHz 
using automated laser rastering. 
6.3. Results and Discussion 
 Host Range and Susceptibility Study 
      Disc diffusion results classified the various strains as sensitive (VSE), intermediate (I-VRE), or 
resistant (VRE) with the respective van types denoted for resistant strains, shown in Table 1.  Infectivity 
rates (host range) for the three phages tested are summarized in Table 2.  ϕ31 was observed to have the 
highest rate of infection at 62% (31 of 50 strains tested), whereas ϕ46 and ϕ51 had infectivity rates of 
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46% (23 of 50 strains tested).  To ensure amplification of ϕ51 could be achieved in the presence of other 
phages, a cocktail consisting of all three phages was incubated in E. faecalis MMH594, a suitable host for 
ϕ51.  Post infection it was revealed that only ϕ51 had amplified, supporting the fact that amplification was 
not inhibited by the presence of other phages.  By implementing a cocktail of all three phages, infectivity 
could be increased to approximately 84% of the 50 E. faecalis strains tested.   
 
Table 6.2. E. faecalis phage host range 
Bacteriophage Strains infected % infectivity 
ϕ31 31/50 62 
ϕ46 23/50 46 
ϕ51 23/50 46 
Cocktail 42/50 84 
 
 
 Method Comparison for Digestion 
      Previous studies utilized acid pretreatment and disulfide bond disruption with β-mercaptoethanol 
(βME) to analyze phage capsid proteins by MALDI-TOF MS 209,214.  When these methods were applied to 
ϕ31, ϕ46, and ϕ51 no discernible capsid phage peaks were observed, which agreed with previous findings 
for other phages 214,215.  In order to effectively utilize phage amplification as a platform for bacterial 
identification, the method must be shown to be reproducible and easy to implement.  Three currently used 
approaches for protein digestion: a methanol denaturation (methanol method) 219, a microwave-assisted 
DTT denaturation (dithiothreitol method) 220, and an overnight trypsin digestion (conventional method) 
221, were slightly modified, as described in the Experimental Section, to investigate their ability to 
promote protease cleavage.  Varying degrees of disruption and cleavage were observed in the MALDI 
spectra for the different experimental parameters and reagents (Figure 6.1).  Methanol disruption showed 
evident BSA peptide peaks m/z 1439, 1567, and 2045, as previously reported in literature 223, but as 
shown by the intensity of the 66 kDa protein, much of the BSA remained after digestion.  Dithiothreitol 
digestion yielded higher intensity compared to the methanol method.  Overall, the conventional approach 
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resulted in the greatest number of identifiable peptide peaks.  When applied to filter-sterilized phage, all 
three methods proved irreproducible and insufficient for cleavage of the capsid assembly.  
 
Figure 6.1. MALDI-TOF MS spectra of tryptic digests of BSA using four different denaturing conditions. 
 
Since the previously published methods for protein digestion yielded poor results with pretreatment of  
the enterococcal phages, other denaturing agents including β-mercaptoethanol (βME), (tris(2-
carboxyethyl)phosphine (TCEP), and urea were evaluated to find a more suitable alternative for a rapid, 
non-intensive procedure for phage analysis.  Urea was determined to be most suitable for digestion at 
elevated temperatures.  Initial studies with bovine serum albumin (BSA), myoglobin, and lysozyme 
showed that slightly different optimal temperatures and heating intervals were necessary for efficient 
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digestion of each protein.  Although BSA and lysozyme were digestible at 37oC, myoglobin required 
temperatures above 48oC.  Above 55oC, as well as after 20 minutes at temperatures above 50oC, 
degradation of trypsin was observed; this was deduced from the rapid decrease in identifiable peptide 
peaks and disappearance of the 23.3kDa trypsin peak for extended digestions at elevated temperatures.  
Taking these findings into account, we formulated a one-pot gradient method that ramped from 48-55oC 
at a rate of 0.8oC/min.  When tested against BSA, numerous peaks, confirmed as BSA tryptic peptides by 
literature 223, were observed for the digestion of the protein. 
     Because of the above results, the one-pot gradient method was applied to phages ϕ31, ϕ46, and ϕ51.  
Representative MALDI spectra of these phages, along with a phage-free control, following digestion are 
shown in Figure 6.2. 
 
 
Figure 6.2. MALDI spectra of three Enterococcus phages from filtered lysate: ϕ31, ϕ46, ϕ51, and a 
phage-free control consisting of JH2SS.  Characteristic peaks for each phage are labeled by mass. 
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Unique peak distributions for each phage allowed for differentiation.  Visually, ϕ31 was defined by 
the presence of peptide peaks at m/z 2014, 2271, and 3037, ϕ46 by peaks at m/z 2088, 2514, and 2783, 
and ϕ51 by peaks at m/z 2232, 2917, and 3640.  These peaks were chosen based on reproducibility and 
comparison to the control studies.  The phage-free control, consisting of E. faecalis JH2SS digested with 
urea and trypsin, was analyzed to ensure none of the peaks used for identification of the respective phages 
were present.  Detection limits for each phage were similar, with no discernible digestion-related peaks 
when the relative phage concentration was below 3.0 x 108 pfu/mL; the limit of detection for ϕ31, ϕ46, 
and ϕ51 was 2.6 x 108, 3.0 x 108, and 2.2 x 108 pfu/mL respectively.   Because of this, amplification 
experiments were conducted at relatively high bacterial concentrations (2 x 107 cfu/mL) to ensure output 
phage levels were above the limit of detection. 
Simultaneous ID and Antibiotic Resistance Determination by Phage Amplification 
      Because a viable host must be present for phage amplification to occur, no phage proteins are 
observed in the antibiotic susceptible strains (amplification is precluded by killing and/or inhibition of 
susceptible strains).  Figures 6.3 and 6.4 show the mass spectral results of phage amplification 
experiments for ϕ31 with four E. faecalis strains including three VRE strains (MMH594, SF24413, and 
V583) and one VSE (JH2SS).  Spectra of all four strains showed phage amplification had occurred 
without selection, which was indicated by appearance of peptide peaks at m/z 2014, 2271, and 3037 
(Figure 6.3).  In the presence of vancomycin, the three VRE strains, MMH594, SF24413, and V583, 
showed characteristic phage peptide peaks, whereas VSE strain, JH2SS, showed no signs of 
amplification, indicated by the lack of peptide peaks m/z 2014, 2271, and 3037 (Figure 6.4).  These 





Figure 6.3. Amplification experiment using ϕ31 performed without 5 µg/mL of vancomycin. 
 
Figure 6.4. Amplification experiment using ϕ31 performed with 5 µg/mL of vancomycin. 
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      Identical studies were conducted using ϕ46 and ϕ51 with comparable findings.  Figures 6.5 and 6.6 
shows amplification experiments for each phage in the presence of 5 µg/mL vancomycin.  Four strains, 
two VRE and two VSE isolates, were evaluated independently for each phage.  Spectra of all strains 
showed that phage amplification had occurred without selection for ϕ46 and ϕ51.  In the presence of 
vancomycin (Figure 6.5), amplification of ϕ46 showed phage peptide peaks at m/z 2088, 2514, and 2783 
for VRE strains SF24413 and SF25120, whereas spectra for VSE strains JH2SS and FA2-2 had none of 
these peaks.  The same was true for amplification of ϕ51.  Peptide peaks m/z 2232, 2917, and 3640 were 
observed in the spectra of VRE strains SF26630 and V583 (Figure 6.6), indicating amplification of ϕ51 
had occurred, whereas the spectra of VSE strains JH2SS and FA2-2 showed no peaks. 
 
 
Figure 6.5. MALDI-TOF MS spectra of selected strains of E. faecalis after six hour amplification 




Figure 6.6. MALDI-TOF MS spectra of selected strains of E. faecalis after six hour amplification 
experiments with ϕ51 in the presence of 5 µg/mL vancomycin. 
 
      This study shows the utility of analyzing tryptic peptides from amplified phages as a means for 
identifying E. faecalis while simultaneously determining antibiotic resistance.  Future work will focus on 
studying other species of Enterococcus, along with the discovery of phages with broader coverage.  The 
ability to multiplex this method for evaluating several antibiotics simultaneously would aid in reducing 
improper courses of therapy.   
6.4. Conclusion 
      Phage amplification coupled with trypsin digestion and MALDI-TOF MS proved capable for 
identification of E. faecalis and vancomycin resistance determination.  Digestion of Enterococcus phages 
ϕ31, ϕ46, and ϕ51 following amplification in the presence of 5µg/mL vancomycin resulted in detection 
within six hours of incubation, negating the need for secondary testing.  With a cocktail of all three 
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phages, infectivity could be expanded to approximately 84% of the 50 E. faecalis strains tested.  This 
would generate the sensitivity and specificity required for clinical viability.  Expansion of this study 
utilizing novel phages with broad-host range infectivity would create a large repository for clinical 
diagnostics with minimal effort.  Implementation of this method on clinical MALDI-TOF MS instruments 
already in place in clinical and diagnostics laboratories world-wide, could promote the ease in acceptance 
of phage-based detection for hospital diagnostics.  With the rapid emergence of multidrug resistant 





















CHAPTER 7  
ADDITIONAL WORK TO SUPPLEMENT PUBLICATIONS 
7.1. Pseudomonas aeruginosa Resistance Profiling by MOLI MS 
       Pseudomonas aeruginosa is the most common isolated pathogen isolated from patients of extended 
hospitalizations, especially patients dealing with cystic fibrosis.  Due to the close similarities within the 
genus, Pseudomonas spp. are notoriously difficult to differentiate by current methods.  Seventy-two 
Pseudomonas aeruginosa strains collected from six hospitals across France were evaluated by MOLI MS 
to further evaluate the strain-level capabilities of the method.  All 72 Pseudomonas aeruginosa strains in 
Table 4.3, grown similar to the Enterobacteriaceae strains described in Chapter 3, were evaluated by 
MOLI MS to further evaluate the strain-level capabilities of the method.   
Table 7.1. Pseudomonas strains for resistance study. 
Species Strain 
Piperacillin/Tazobactum  
P. aeruginosa 709 
P. aeruginosa 714 
P. aeruginosa 706 
P. aeruginosa 683 
P. aeruginosa 707A 
P. aeruginosa 694 
P. aeruginosa 719* 
P. aeruginosa 693* 
Gentamicin  
P. aeruginosa 51* 
P. aeruginosa 426* 
P. aeruginosa 126* 
P. aeruginosa 123* 
P. aeruginosa 54* 
P. aeruginosa 122* 
P. aeruginosa 430* 
P. aeruginosa 69* 
P. aeruginosa 410* 
P. aeruginosa 422 
P. aeruginosa 34 
P. aeruginosa 24 
P. aeruginosa 420 
P. aeruginosa 53B 
P. aeruginosa 59A 
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Table 7.1 continued  
P. aeruginosa 121 
P. aeruginosa 26 
P. aeruginosa 78 
P. aeruginosa 44 
P. aeruginosa 57 
P. aeruginosa 108 
Ceftazidime  
P. aeruginosa CSM 49* 
P. aeruginosa CSM 60* 
P. aeruginosa CSM 61* 
P. aeruginosa CSM 62* 
P. aeruginosa CSM 63* 
P. aeruginosa CSM 51 
P. aeruginosa CSM 52 
P. aeruginosa CSM 54 
P. aeruginosa CSM 57 
P. aeruginosa CSM 68 
Ciprofloxacin  
P. aeruginosa 51* 
P. aeruginosa 126* 
P. aeruginosa 123* 
P. aeruginosa 69* 
P. aeruginosa 426* 
P. aeruginosa 44 
P. aeruginosa 57 
P. aeruginosa 108 
P. aeruginosa 422 
P. aeruginosa 34 
Piperacillin  
P. aeruginosa CSM 46* 
P. aeruginosa CSM 47* 
P. aeruginosa CSM 48* 
P. aeruginosa CSM 49* 
P. aeruginosa CSM 53* 
P. aeruginosa CSM 56* 
P. aeruginosa CSM 61* 
P. aeruginosa CSM 63* 
P. aeruginosa CSM 64* 
P. aeruginosa CSM 51 
P. aeruginosa CSM 52 
P. aeruginosa CSM 54 
P. aeruginosa CSM 55 
P. aeruginosa CSM 57 
P. aeruginosa CSM 58 
P. aeruginosa CSM 59 
P. aeruginosa CSM 65 
P. aeruginosa CSM 66 
P. aeruginosa CSM 69 
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Table 7.1 continued  
Ticarcillin  
P. aeruginosa 24* 
P. aeruginosa 420* 
P. aeruginosa 53B* 
P. aeruginosa 59A* 
P. aeruginosa 26* 
P. aeruginosa 78* 
P. aeruginosa 94B 
P. aeruginosa 51 
P. aeruginosa 426 
P. aeruginosa 126 
P. aeruginosa 123 
P. aeruginosa 54 
P. aeruginosa 122 
P. aeruginosa 430 
P. aeruginosa 69 
P. aeruginosa 410 
P. aeruginosa 44 
P. aeruginosa 57 
P. aeruginosa 108 
P. aeruginosa 34 
P. aeruginosa 121 
~ Resistant strains are denoted by * 
 
Both supervised and unsupervised learning algorithms were applied to the resulting data set to assign 
bacterial identification.  Strain-level classification by leave-one-spectrum-out cross-validation (LOSOCV) 
correctly identified 347/360 replicates resulting in 96.4% accuracy.  Additional classification by linear 
discriminant analysis (LDA) and fuzzy multivariate rule-building expert systems (FuRES) resulted in 
96.4 and 92.3% accuracy, respectively.  
      The strains were screened against 13 antibiotics in total to determine a broad susceptibility profile.  
The multidrug resistance among the genus makes them ideal candidates for MOLI MS.  Susceptibility 
studies for ceftazidime, piperacillin, gentamicin, and ciprofloxacin on the spectral data from MOLI MS 
were performed using principal component analysis and leave-one-spectrum-out cross-validation to 
determine if they could be differentiated based on susceptibility.  The classification rates for antibiotic 
resistance determination were above 96% for all data sets, as seen in Table 4.3.  Unlike Staphylococcus 
aureus in which C15:0 was the major fatty acid for all strains, for Pseudomonas C16:0, C16:1, and C18:1 
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interchanged as the major fatty acids from strain to strain.  Increased relative intensity of C16:0 was 
indicated for all resistant strains, while other fatty acid components were needed for further separation of 
the data set.  This presents promising results that MOLI MS can be utilized for antibiotic resistance 
differentiation as well as identification. 
Table 7.2. Antibiotic susceptibility results for Pseudomonas 
Antibiotic of Interest 
 
% Correct Classification Influential Factors 
Ceftazidime 98% (49/50) C16:0 (R);  
C16:1 and C20:1(S) 
Ciprofloxacin 96% (48/50) C16:0 and C18:1 (R);  
C16:1 (S) 
Gentamicin 99% (104/105) C16:0 and C18:1 (R);  
C16:1 and C19:1 (S) 
Piperacillin 96% (96/100) C16:0 (R); 
 C16:1 and C20:1 (S) 
 
7.2. Differentiation of Enterococci and Fungi by MOLI MS and Protein Profiling 
 Growth and Extraction 
      Enterococcus isolates in Table 7.3 were grown as previously specified in Chapter 3 of the published 
manuscript.  Fungal isolates were grown at 37oC on sabouraud dextrose agar for up to 72 h. due to the 
slow growth rates.  The extraction involved bath sonication of colonies in 100L of 2M HCl for five 
minutes followed by addition of 100 L of a 33/66 v/v% methanol/chloroform mixture.  The mixture was 
then vortexed for 60 seconds followed by a brief centrifugation step to allow for phase separation.  
MALDI-TOF MS analysis was performed on the extracts as described above in the published work.   
Table 7.3. Strains for fungi and Enterococcus study 
Species Strain 
Fungi strains  
A.  alternata CSM 1 
A.  flavus CSM 1 
A.  fumigatus CSM 1 
C.  neoformans CSM 1 
C.  albican CSM 1 
C.  bracarensis   F421.1 
C.  bracarensis   F649.1 
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Table 7.3 continued  
C.  glabrata CSM 1 
C.  glabrata   JH001 
C.  krusei CSM 1 
C.  niveriensis   JH001 
C.  orthopilosis   JH001 
C.  parapsilosis CSM 1 
C.  parapsilosis   JH001 
C.  tropicalis CSM 1 
F.  solani JHU001 
P.  lilacinus JHU001 
P.  variotii JHU001 
Rasamsonia JHU001 
Rhizopus  sp JHU001 
R.  mucilaginosa JHU001 
S.  apiospermum JHU001 
S.  kudriavzevii JHU001 
S. cerevisiae   JHU146 
S.  cerevisiae   JHU147 
S.  cerevisiae   JHU689.1 
S.  cerevisiae   probiotic 
T.  tonsurans JHU001 
T.  dermatis   JCM11170 
T.  mucoides   JCM9939 
Enterococcus strains  
E. faecalis   182970 
E. faecalis   2924 
E. faecalis   599951 
E. faecalis   79-3 
E. faecalis   ATCC35038 
E. faecalis   B84847 
E. faecalis   CH19 
E. faecalis   E1Sol 
E. faecalis   FA2-2 
E. faecalis   HH22 
E. faecalis   HIP11704 
E. faecalis   Merz151 
E. faecalis   Merz96 
E. faecalis   MMH594 
E. faecalis   OG1RF 
E. faecalis   RM4679 
E. faecalis   F21520 
E. faecalis   F21521 
E. faecalis   F24413 
E. faecalis   F26630 
E. faecalis   F28073 
E. faecalis   F350 
E. faecalis   T11 
E. faecalis   T4 
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Table 7.3 continued  
E. faecalis   T6 
E. faecalis   T7 
E. faecalis   T8 
E. faecalis   UAA1014 
E. faecalis   UAA1180 
E. faecalis   UAA1489 
E. faecalis   UAA409 
E. faecalis   UAA702 
E. faecalis   UAA769 
E. faecalis   UAA902 
E. faecalis   UAA943 
E. faecalis   V583 
E. faecalis   Y16-1 
E. faecium   1 .231.408 
E. faecium   E0164 
E. faecium   E0269 
E. faecium   E0680 
E. faecium   E0688 
E. faecium   E1133 
E. faecium   E1185 
E. faecium   E1321 
E. faecium   E1552 
E. faecium   E1573 
E. faecium   E1574 
E. faecium   E1575 
E. faecium   E1590 
E. faecium   E1620 
E. faecium   E1623 
E. faecium   E1627 
E. faecium   E1630 
E. faecium   E1731 
E. faecium   E1861 
E. faecium   E1904 
E. faecium   E2071 
E. faecium   E2297 
E. faecium   E2560 
E. faecium   E4215 
E. faecium   E6045 
E. faecium   UAA1280 
E. faecium   UAA910 
E. faecium   VAN342 






 Comparison of MOLI MS and Protein Profiling 
      Fungal isolates, consisting of clinically-relevant yeasts and respiratory molds shown in Table 7.3, 
were analyzed based on their protein and fatty acid profiles for comparative classification.  Figure 7.1 
shows a two-dimensional PCA plot with five replicates for each of the 30 isolates for visual distinction.  
The yeast and molds were clearly separated into unique groups as indicated by the circles.  The 66 
Enterococcus strains were also investigated by PCA, but the sheer size of data set was not conducive for 
obtaining relevant information by visual representation.      
 
Figure 7.1. PCA plot of 30 fungal isolates. The mold and yeast isolates are clearly defined. 
 
      Protein-profiling on the Ultraflextreme correctly classified only 33% (33/100) of the fungal organisms 
at the species level.  Most isolates were identified at the genus level, but the reported scores were not high 
enough to give a confident diagnosis.  For the Enterococcus data set, protein profiling provided more 
accurate results with 84% (154/185) of the strains being correctly identified at the species level.  In 
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contrast, CeO2-catalyzed fatty acid profiling successfully identified 99% (99/100) and 100% (330/330) of 
the fungi and enterococci at the species level respectively, while providing accurate strain-level 
classification as well by LOSOCV.  This clearly shows the adaptability of MOLI MS with the altered 
extraction for pathogenic fungi differentiation and processing of large data sets. 
Table 7.4. Percent accuracies of protein and fatty acid profiling analysis for Enterococcus and fungi. 
  CeO2-catalyzed MOLI  Ultraflextreme 
Fungi Strain 99% (149/150) Strain - 
 Species 99% (149/150) Species 33% (33/100) 
 Genus 100% (150/150) Genus 72% (72/100) 
 Mis-ID 1% (1/150) Mis-ID 28% (28/100) 
 Failure to ID 0% Failure to ID 0% 
Enterococcus Strain 96% (317/330) Strain - 
 Species 100% (330/330) Species 84% (154/185) 
 Genus 100% (330/330) Genus 100 % (185/185) 
 Mis-ID 4% (13/330) Mis-ID 4% (7/185) 
 Failure to ID 0% Failure to ID - 
 
 
7.3. Database Study with Blind Analysis 
       As a last proof in method validation, 50 organisms listed in Table 7.4 were analyzed by MOLI MS 
and classified by LOSOCV and k-nearest-neighbor (KNN) as a database study.  All strains were grown 
for 18 h. at 37oC, as stated in previous chapters, according to Bruker’s standard operating protocols.  All 
50 isolates were analyzed with six replicates for each organism and compiled into a training set for 
analysis.  LOSOCV of the 50 strains correctly classified 96% (289/300) of the isolates.  Visual 
differentiation of the strains by PCA was convoluted due to the size of the data set so the plot is not 
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shown.  Eleven strains, denoted by * in Table 7.4, were regrown and labeled as numbers to serve as blind 
isolates for extraction.  The blind isolates were compiled into a test set to screen against the training set 
for k-nearest neighbor classification.  A k value of 1 and 5 were tested, both providing correct 
classification results of 98% (65/66).  These results are significant, as the ability to identify unknown 
samples is paramount for the use of MOLI MS as a routine method in clinical applications.   
 
Table 7.5. Organisms for database study 
Species Strain 
C. amalonaticus  ATCC 041217c 
C. amalonaticus  ATCC 25405 
C. jeikeium  JMI 78-9232A 
C. jeikeium  JMI 78-9232F 
E. aerogenes  ATCC 13048 
E. cloacae  ATCC 13047 
E. cloacae  ATCC 23355 
E. durans  JMI 12-581A 
E. durans  JMI 75-10421A 
E. faecalis  ATCC 49332 
E. faecalis  ATCC 49474 
E. faecium  ATCC 35667 
E. faecium  JMI 3122 
E. fergusonii  ATCC 35472 
E. hermannii  JMI CR-001 
K. pneumoniae  ATCC 13883 
K. pneumoniae  ATCC 9997 
L. grayi ssp grayi  WSLC 6036 
L. grayi ssp murrayi  WSLC 6037 
L. innocua  ATCC 33090 
L. ivanovii  ATCC 19119 
L. seeligeri WSLC 40126 
L. welshimeri  WSLC 50146 
P. vulgaris  ATCC 6896 
P. vulgaris  ATCC 8427 
S. agalactiae  ATCC 13813 
S. bovis  ATCC 49133 
S. enterica  ATCC 11511 
S. entertidis  ATCC 13076 
S. epidermidis  ATCC 12228 
S. haemolyticus  JMI 107 
S. haemolyticus  JMI 425 
S. hominis  JMI 3143 
S. lugdunensis  JMI 4-9861 
S. pyogenes  ATCC 51339 
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Table 7.5 continued  
S. salivarius  JMI 89-9996 
S. simulans  JMI 7295 
S. sonnei  ATCC 25931 
S. sonnei ATCC 11060 
E. coli  ATCC 15597* 
E. coli  K12* 
E. faecalis V583* 
L. monocytogenes ATCC 19115* 
M. luteus ATCC 4698* 
P. mirabilis ATCC 29245* 
S. aureus ATCC 14775* 
S. boydii ATCC 9207* 
S. dysenteriae ATCC 12180* 
S. typhimurium ATCC 14028* 
S. warneri JMI 3158* 





















CHAPTER 8  
SUMMARY AND FUTURE WORK 
8.1. Summary 
      The growing rate of use for MALDI-TOF MS in clinical settings is currently paving the way for a 
high throughput, cost-effective approach to replace the laborious and time consuming traditional methods.  
Sample preparation does not require extraction, for most sample types, and the method has already 
received FDA approval for clinical use.  The major drawback of this method is that it only possesses the 
capability of performing species-level identification and has several proven problematic groups, 
Enterobacteriaceae, Streptococcus spp., Pseudomonas spp., Acinetobacter spp., due to the close 
similarities in ribosomal protein sequences.  Antimicrobial susceptibility testing also requires secondary 
testing, when using protein profiling as the identification platform, which increases time to diagnosis by 
about 52 h.   
      Recent advancements of MOLI MS presented in this work, have shown strain-level differentiation 
capabilities, even in the case of closely-related phylotypes deemed indiscernible by protein profiling.  The 
issue of secondary testing has also been addressed showing that it is capable of simultaneous 
identification and antibiotic resistance profiling of methicillin-resistant and -sensitive Staphylococcus 
aureus, vancomycin-resistant and -sensitive Enterococcus faecalis, as well as multidrug resistant 
Pseudomonas aeruginosa.  By removing the antibiotic resistance testing step, it decreases the time of 
detection down to the time required for culturing of the bacteria of interest.  To date over 300 bacterial 
isolates have been analyzed by MOLI MS with correct strain-level classification of greater than 96%, as 
well as susceptibility determination, in less than 20 hours.   The promising results from the database 
analysis with blind studies proved that MOLI MS is indeed capable of identifying unknown samples 
which is crucial for implementation in a clinical laboratory.   
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8.2. Future Work 
      There are still several avenues that could be explored to further develop this work into a functioning 
method for implementation in clinical laboratories.  Since this method is still in the preliminary phase of 
development, a larger library of organisms needs to be analyzed before definitive conclusions can be 
drawn; the Bruker Biotyper library consists of over 3,400 organisms, whereas our MOLI MS library has 
only reached 400 organisms.  Also, it should be noted that two completely data processing systems are 
being used for validation which will affect the accuracies differently.  Expansion of a phage-host library 
will also be beneficial in improving the identification capabilities of phage-based MALDI-TOF MS.    
      Additional work to elucidate the catalytic efficiency and mechanism of cleavage for the CeO2 catalyst 
should be investigated to ensure maximum conversion of the lipids into their fatty acid components is 
being achieved.  This would involve a two-fold approach.  Previous reports using CeO2 in 
transesterification reactions with oils for the production of biofuels have attributed the activity of CeO2 to 
the rapid change in cerium’s oxidation state from Ce3+ to Ce4+.  This activity is due to the oxygen vacancy 
defects which are increased at elevated temperature and low pressure, which are both present during 
MALDI-TOF MS operation.  Several studies were conducted with different size CeO2 particles to show 
that different levels of cleavage were achieved based on the size, but it was not directly correlated with 
the notion that larger surface area results in greater activity.  Thus, the CeO2 could be controllably 
synthesized and probed by x-ray photoelectron spectroscopy (XPS) or x-ray diffraction (XRD) to 
determine if higher occurrence of oxygen vacancy defects did actually result in improved catalytic 
cleavage.  The second aspect would be attempting to run DRIFTS analysis or labelling studies using O18 -
fatty acid standards to elucidate if a cerium/fatty acid adduct is ever being formed or if it is undergoing a 
different mechanism of cleavage. 
      Lastly, this dissertation revealed inherent differences between resistant and sensitive strains for 
Staphylococcus aureus and Pseudomonas aeruginosa, but the cause for these differences should be 
further investigated.  In all cases C16:0 was increasing for the resistant strains, but the significance of 
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other fatty acids in determining susceptibility was not as definitive.  Since the class of antibiotic dictates 
its pathway of entering the cell, differences in the significant fatty acids for each antibiotic-host 
combination are expected.  Understanding what specifically is causing these changes could provide useful 
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